    		                		            		                                                                                                                                          	    		   		   	  	       	            							    	    																																			    																	    	    	                             		       	                                                                                                   	        						    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               	            			        	                            						    	    																																			    																	    	    	                             		       	                                                                                                                                                                                                                                                                                                   	     <!DOCTYPE html><html><head>        	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />    <meta charset="utf-8" />        	<title>DailyMed - ELIQUIS- apixaban tablet, film coated  </title>                <!--[if lt IE 9]>        <script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>    <![endif]-->    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/skeleton.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/jquery.jqzoom.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/style.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/header-search.min.css" />    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive.min.css" />    <link rel="stylesheet" type="text/css" media="print" href="dailymed/css/print.min.css" />    <!--[if !IE]><!-->    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive-tables.min.css" />    <!--<![endif]-->    <link rel="icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon" />    <link rel="shortcut icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon"/>        <link rel="apple-touch-icon" sizes="57x57" href="dailymed/images/favicons/apple-touch-icon-57x57.png">    <link rel="apple-touch-icon" sizes="114x114" href="dailymed/images/favicons/apple-touch-icon-114x114.png">    <link rel="apple-touch-icon" sizes="72x72" href="dailymed/images/favicons/apple-touch-icon-72x72.png">    <link rel="apple-touch-icon" sizes="144x144" href="dailymed/images/favicons/apple-touch-icon-144x144.png">    <link rel="apple-touch-icon" sizes="60x60" href="dailymed/images/favicons/apple-touch-icon-60x60.png">    <link rel="apple-touch-icon" sizes="120x120" href="dailymed/images/favicons/apple-touch-icon-120x120.png">    <link rel="apple-touch-icon" sizes="76x76" href="dailymed/images/favicons/apple-touch-icon-76x76.png">    <link rel="apple-touch-icon" sizes="152x152" href="dailymed/images/favicons/apple-touch-icon-152x152.png">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-196x196.png" sizes="196x196">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-160x160.png" sizes="160x160">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-96x96.png" sizes="96x96">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-16x16.png" sizes="16x16">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-32x32.png" sizes="32x32">    <meta name="msapplication-config" content="/dailymed/images/favicons/browserconfig.xml" />    <meta name="msapplication-TileColor" content="#da532c">    <meta name="msapplication-TileImage" content="/dailymed/images/favicons/mstile-144x144.png">    <meta name="description" content="" />    <meta name="keywords" content="" />     <meta name="robots" content="noimageindex, noodp, noydir" />     <meta name="viewport" id="viewport" content="width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0" />    <script src="/dailymed/scripts/modernizr-2.0.6.min.js"></script>        <script type="text/javascript" src="//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>        <script type="text/javascript">        if (typeof jQuery == 'undefined')        {              document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');        }    </script>                	                	            	    	<script type="text/javascript">		var basepath = "/dailymed";;		var availableClasses =  new Array();;		for(var i = 0; i < availableClasses.length; i++){			availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();		}		var labeltitle = "ELIQUIS- apixaban tablet, film coated <br>";;		var emailLink = "";;		var emailrequest = "0";;	</script>    <script src="/dailymed/scripts/javascript-html-attribute-encoding.min.js"></script>	<script src="/dailymed/scripts/scripts.min.js"></script>        <script type='text/javascript' src="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js"></script>    <script type="text/javascript">        if (typeof jQuery.ui == 'undefined')        {            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="dailymed/css/jquery-ui-1.10.4.custom.min.css">');        }        else{            document.write('<link rel="stylesheet" href="/ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');        }    </script>    <script type='text/javascript' src='/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'></script>      <script type="text/javascript" src="/dailymed/scripts/jquery.placeholder.min.js"></script>    <script src="//www.accessdata.fda.gov/spl/stylesheet/spl.js" type="text/javascript" charset="utf-8">/* */</script>    <!-- Magnific Popup core CSS file -->    <link rel="stylesheet" href="dailymed/css/magnific-popup.min.css">        <!-- Magnific Popup core JS file -->    <script src="/dailymed/scripts/jquery.magnific-popup.js"></script>        <meta name = "format-detection" content = "telephone=no"></head><body class="inner drug-info">	<div class="container_1000 bg_shadow">        <div style="width: 0; height: 0;"><a href="#" id="top-of-page"></a></div><header>	<div class="topHeader">				<ul id="skip">		<li><a href="#skip-main-content">Skip to Main Content</a></li></ul>		<nav class="topHeaderNav">        	<div class="topNIHLogo mobileview">        		<a href="http://www.nih.gov" class="top-logo" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>            	<a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>			<div class="container">				<div class="sixteen columns">                	<div class="topNIHLogo"><a href="http://www.nih.gov" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>                    <a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>					<ul>																		<li class="safety"><a title="Report Adverse Events" href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events </a><span>|</span><a title="FDA Safety Reporting and Recalls" href="http://www.fda.gov/Safety/Recalls" target="_blank">Recalls</a></li>					</ul>				</div>			</div>		</nav>		<div class="divider"></div>	</div>	<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png" alt="DailyMed" /></div>	<div class="bottomHeader">		<div class="header-image">						<div class="mobile-menu-btn closed hasjs" tabindex="0"></div><div class="mobile-menu">		<div class="mobile-menu-container">		<div class="pro-menu active">			<div class="first half">				<ul>					<li><a href="dailymed/index.cfm">Home</a></li>					<li>						News						<ul>							<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>							<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>						</ul>					</li>					<li><a href="dailymed/about-dailymed.cfm">About Dailymed</a></li>					<li><a href="dailymed/contact-us.cfm">Contact Us</a></li>					<li>						Safety Reporting &amp; Recalls						<ul>							<li><a href="/www.accessdata.fda.gov/scripts/medwatch/">Report Adverse Events</a></li>							<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey Recalls</a></li>						</ul>					</li>					<li>						<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>											</li>				</ul>			</div>			<div class="last half">				<ul>					<li>						NLM SPL Resources						<ul>							<li>								<a href="dailymed/spl-resources.cfm">Download Data</a>								<ul>									<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>									<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>									<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>								</ul>							</li>							<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>							<li><a href="dailymed/spl-resources-all-mapping-files.cfm">Articles &amp; Presentations</a></li>						</ul>					</li>					<li>						Application Development Support						<ul>							<li>								<a href="dailymed/app-support.cfm">Resources</a>								<ul>									<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																		<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>								</ul>							</li>						</ul>					</li>					<li><a href="dailymed/help.cfm">Help</a></li>				</ul>			</div>		</div>			</div></div>			<a href="dailymed/index.cfm" class="logo" title="DailyMed">DailyMed</a>						<div class="header-search-container">				<div id="header-search">									    					    				    <form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all" value="all" />					<label for="labeltype-all">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human" value="human"/>					<label for="labeltype-human">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden" name="labeltype" id="labeltype-animal" value="animal" />					<label for="labeltype-animal">Animal Drugs</label>							</li>							<li class="more-ways" id="header-search-more-ways">					<a href="#" id="more-ways-button" class="more-ways-label">More ways to search</a>					<ul id="more-ways-dropdown" class="dropdown" style="display:none;">						<li>							<a href="dailymed/advanced-search.cfm">Advanced Search</a>						</li>						<li>							<a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a>						</li>						<li>							<a href="dailymed/archives/index.cfm">Label Archives</a>						</li>						<li>							<a class="external-link" href="http://pillbox.nlm.nih.gov" target="_blank">Tablet/Capsule ID Tool</a>						</li>					</ul>				</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">									<button class="search-button">  </button>							</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>									</div>			</div>			<div class="mobile-search-btn" tabindex="0"></div>												<div class="header-bg">																										</div>			<div class="divider"></div>		</div>		<div class="bottomHeaderContent">									<div class="search mobile-search">				<div class="divider_10 nomargin mobileview"></div>				<div class="searchTool mobileview"></div>															<form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all-2" value="all" />					<label for="labeltype-all-2">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human-2" value="human"/>					<label for="labeltype-human-2">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden"  name="labeltype" id="labeltype-animal-2" value="animal" />					<label for="labeltype-animal-2">Animal Drugs</label>							</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchToolsQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">			</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>								<div class="divider"></div>								<nav class="bottomHeaderNav">                <noscript>                <div class="tabletnav no-js">                    <div class="col">                        <ul>                            <li><a href="dailymed/index.cfm">Home</a></li>                            <li>News                                <ul>                                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                                    <li><a href="dailymed/rss-updates.cfm">Get RSS News & Updates</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Search                                <ul>                                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>                                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                                        <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                            <li>NLM SPL Resources                                <ul>                                    <li><a href="dailymed/spl-resources.cfm">Download Data</a>                                        <ul>                                            <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                            <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                            <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                                        </ul>                                    </li>                                    <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                                    <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Application Development Support                                <ul>                                    <li><a href="dailymed/app-support.cfm">Resources</a>                                        <ul>                                            <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                            <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                                        </ul>                                    </li>                                </ul>                            </li>                            <li><a href="dailymed/help.cfm">Help</a></li>                        </ul>                    </div>                </div>           		</noscript>                					<ul class="webview hasjs">						<li><a href="dailymed/index.cfm" title="Home">Home</a></li>						<li>													<a href="#" title="News">												News</a>							<ul class="sub-menu">								<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>								<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>							</ul>						</li>						<li>																				<a href="dailymed/fda-drug-guidance.cfm" title="FDA Guidances &amp; Info">												FDA Guidances &amp; Info</a>													</li>						<li>													<a href="#" title="Structured Product Labeling (SPL) resources for industry professionals.">												NLM SPL Resources</a>														<ul class="sub-menu">								<li><a href="dailymed/spl-resources.cfm">Download Data</a>									<ul>										<li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>										<li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Indexing Files</a></li>										<li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>									</ul>								</li>								<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>								<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>							</ul>						</li>						<li>													<a href="#" title="Application Development Support">												Application Development Support</a>							<ul class="sub-menu">								<li><a href="dailymed/app-support.cfm">Resources</a>									<ul>										<li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>																				<li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>									</ul>								</li>							</ul>						</li>									  						<li>													<a href="dailymed/help.cfm" title="Help">												Help</a></li>   					</ul>					<ul class="tabletview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li><span>News</span>									<ul>										<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>										<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>									</ul>								</li>								<li><span>Safety Reporting and Recalls</span>									<ul>										<li><a href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events</a></li>										<li><a href="/www.fda.gov/Safety/Recalls" target="_blank">FDA Saftey Recalls</a></li>									</ul>								</li>								<li>									<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>								</li>																<li><span>NLM SPL Resources</span>									<ul>										<li><a href="dailymed/spl-resources.cfm">Download Data</a>											<ul>												<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>												<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>												<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>											</ul>										</li>										<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>										<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>									</ul>								</li>   								<li><span>Application Development Support</span>									<ul>										<li><a href="dailymed/app-support.cfm">Resources</a>											<ul>												<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																								<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>											</ul>										</li>									</ul>								</li>   								<li><a href="dailymed/help.cfm" title="Help">Help</a></li>   							</ul>						</li>						<li class="mobileview viewmore" tabindex="0"><a title="View More" href="#">More ways to search</a>							<ul>								<li tabindex="0"><a title="Browse Drug Classes" href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>								<li tabindex="0"><a title="Label Archives" href="dailymed/archives/index.cfm">Label Archives</a></li>																<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool" href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>										<ul class="mobileview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li tabindex="0" class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li tabindex="0"><a href="dailymed/browse-drug-classes.cfm" title="Browse Drug Classes">Browse Drug Classes</a></li>								<li tabindex="0"><a href="dailymed/archives/index.cfm" title="Label Archives">Label Archives</a></li>																<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title="Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>				</nav>				<div class="divider_10 nomargin"></div>			</div>					</div>				<div class="divider"></div>	</div></header><div id="skip-main-content"></div>        <div class="container">             <div class="main-content">                <div class="header long">                    <div class="header-top">                            <h1>Label: <span class="long-title">ELIQUIS- apixaban tablet, film coated <br></span></h1>                    </div>                                        <ul class="tools">                    	                        <li class="rss"><a href="#modal-label-rss" class="modal-open">Label RSS</a></li>                        <li class="share">Share                            <noscript>: JavaScript needed for Sharing tools</noscript>                            <!-- AddThis Button BEGIN -->                            <div class="addthis_toolbox addthis_default_style addthis_16x16_style">                                                                                                    	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AELIQUIS%2D%20Apixaban%20Tablet%2C%20Film%20Coated%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3De9481622%2D7cc6%2D418a%2Dacb6%2Dc5450daae9b0%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                                <a class="addthis_button_facebook"></a>                                <a class="addthis_button_twitter"></a>                                                                <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="display: block;">                                    <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span><img style="width:17px" src="/dailymed/images/addthis-image.jpg"></img>                                </a>                            </div>                            <script type="text/javascript">var addthis_config = {"data_track_addressbar":false};</script>                            <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5" ></script>                             <!-- AddThis Button END -->                                                    </li>                    </ul>                  </div>                <div class="four columns sidebar" id="leftmenu">                    <section>                        <article>                                                        <div class="w-photos">                            	                                                                <div class="mod drug-photos">                                <h2><a>View Package Photos</a></h2>                                <ul>                                    <li>                                                                               <ul>                                                                                                                        	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=eliquis-2pt5mg-60slbl.jpg&setid=e9481622-7cc6-418a-acb6-c5450daae9b0" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="0">                                                 	<img id="zoom_1" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=eliquis-2pt5mg-60slbl.jpg&setid=e9481622-7cc6-418a-acb6-c5450daae9b0" src="image.cfm?type=img&name=eliquis-2pt5mg-60slbl.jpg&setid=e9481622-7cc6-418a-acb6-c5450daae9b0" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=eliquis-5mg-60slbl.jpg&setid=e9481622-7cc6-418a-acb6-c5450daae9b0" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="1">                                                 	<img id="zoom_2" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=eliquis-5mg-60slbl.jpg&setid=e9481622-7cc6-418a-acb6-c5450daae9b0" src="image.cfm?type=img&name=eliquis-5mg-60slbl.jpg&setid=e9481622-7cc6-418a-acb6-c5450daae9b0" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                </ul>                                    </li>                                </ul>								                                </div>            								                                                                                            </div>                            <div class="mod-wrap">                                <div class="mod blue-list page-jump">                                    <h2><a href="#drug-information">Drug Label Info</a></h2>                                </div>                                                                <div class="mod blue-list orange">                                                                                                                                                                                                                                                                                                                                                                            <h2><a href="#">Safety</a></h2>                                    <ul>                                                                                    <li>                                                <a class="tip" rel="tooltip" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects." href="#boxedwarning">Boxed Warnings</a>                                            </li>                                                                                                                                                                    <li>                                                <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>                                            </li>                                            <li><a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a></li>                                            <li>                                                <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22apixaban%22+%29" target="_blank">Presence in Breast Milk</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">Related Resources</a></h2>                                    <ul>                                                                                                                            <li>                                                <a href="/vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=apixaban" target="_blank">Medline Plus</a>                                            </li>                                                                                <li>                                            <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=apixaban" target="blank">Clinical Trials</a>                                        </li>                                                                                    <li>                                                <a href="#" id="pubmed-menu">PubMed</a>                                            	    											                                                                                                <ul>                                                    <li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=apixaban[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=apixaban/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=apixaban/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=apixaban/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=apixaban[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a>                                                    </li>                                                </ul>                                            </li>                                            <li>                                                <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=apixaban&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">More Info For This Drug</a></h2>                                    <ul>                                    	                                        <li><a href="#modal-label-archives" class="modal-open">View Label Archives</a></li>                                        <li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>                                                                                <li><a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a></li>                                    </ul>                                </div>                                                            </div>                        </article>                    </section>                </div>                               <div class="content-wide">                        <article>                            <ul class="drug-information">                            	                                                                <li>                                <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    0003-0893-21,                                                                                                                                        	                                    0003-0893-31,                                                                                                                                        	                                    0003-0893-41,                                                                                                                                        	                                    0003-0894-21,                                                                        	<a class="view-more show-js" href="#">view more</a><div class="more-codes"><span>                                                                                                                                        	                                    0003-0894-31,                                                                                                                                        	                                    0003-0894-41,                                                                                                                                        	                                    0003-0894-91                                                                                                                                                                        	</span>                                    </div>                                                                								</li>                                <li>                                                                                                                                                                <li><strong>Packager: </strong>E.R. Squibb &amp; Sons, L.L.C.</li>                                						    	    																																			    																	    	    	                             		       	                                                                                                                                                           </ul>                                                        <ul class="drug-information">                            	                                <li><strong>Category:</strong>                                 	                                    	<span id="category" class="orangetext">                                                                            	HUMAN PRESCRIPTION DRUG LABEL</span></li>                                                                    <li><strong>DEA Schedule:</strong> <span id="dea-schedule">                                                                        	None                                                                        </span></li>                                                                    <li><strong>Marketing Status:</strong> <span id="marketing-status">New Drug Application</span></li>								                            </ul>							                                    <div id="drug-information" class="toggle">                                                                                    <h2><a id="druglabel"></a>Drug Label Information</h2>                                                 <p class="date">Updated                                                  	                                                    	08/14                                                                                                     </p>                                                   <p class="orangetext">If you are a consumer or patient please visit <a href="dailymed/drugInfo.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0&audience=consumer">this version.</a></p>                                                                                                   <ul class="tools">                                                    <li class="download">Download DRUG LABEL INFO: <a class="pdf" href="dailymed/getFile.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0&amp;type=pdf&amp;name=e9481622-7cc6-418a-acb6-c5450daae9b0" target="_blank">PDF</a>                                                    	<a class="xml" href="dailymed/getFile.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0&amp;type=zip&amp;name=ELIQUIS">XML</a>                                                    </li>                                                                                                                                                            <li class="medguide">Medication Guide:                                                         <a href="dailymed/medguide.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0" target="_blank">HTML</a>                                                                                                            </li>                                                                                                        <li class="print">                                                        <a href="dailymed/fda/fdaDrugXsl.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0&amp;type=display" target="_blank">Print Drug Label Info</a>                                                    </li>                                                                                                    </ul>                                                                                                  <div class="drug-label-sections">                                                   <div class="control-nav show-js">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                                                        <ul>                                                                                        	                                                <li id="boxedwarning"><a href="#">BOXED WARNING</a><a class=" tip" rel="tooltip" href="#" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.">(What is this?)</a> <div class="Warning toggle-content open">   <a name="ID_4b7b5ac6-87a7-485a-b13e-6651b4b6e67f"></a>  <a name="section-1"></a>   <p></p>   <h1 style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"> <span class="XmChange">WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS</span> <br /> <br /> <span class="XmChange">(B) SPINAL/EPIDURAL HEMATOMA</span> </h1>   <p class="First" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"> <span class="Bold" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange">(A) </span>PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS</span> </p>   <p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"> <span class="XmChange"><span class="Bold">Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant <span class="Italics">[see <a href="#s2.5">Dosage and Administration (2.5)</a>, <a href="#ID_7b327732-537f-4c63-a4dd-2a41f437bc25">Warnings and Precautions (5.1)</a>, and <a href="#ID_a7613d0d-0fcb-40e6-9339-beecd55c7497">Clinical Studies (14.1)</a>]</span>.</span></span> </p>   <p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"> <span class="XmChange"><span class="Bold">(B) SPINAL/EPIDURAL HEMATOMA</span></span> </p>   <p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"> <span class="XmChange"><span class="Bold">Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:</span></span> </p>   <dl>    <dt>    ●   </dt>    <dd>     <span class="XmChange"><span class="Bold">use of indwelling epidural catheters</span></span>    </dd>    <dt>    ●   </dt>    <dd>     <span class="XmChange"><span class="Bold">concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants</span></span>    </dd>    <dt>    ●   </dt>    <dd>     <span class="XmChange"><span class="Bold">a history of traumatic or repeated epidural or spinal punctures</span></span>    </dd>    <dt>    ●   </dt>    <dd>     <span class="XmChange"><span class="Bold">a history of spinal deformity or spinal surgery</span></span>    </dd>    <dt>    ●   </dt>    <dd>     <span class="XmChange"><span class="Bold">optimal timing between the administration of ELIQUIS and neuraxial procedures is not known</span></span>    </dd>   </dl>   <p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"> <span class="Bold"><span class="Italics" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange">[see </span><a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">Warnings and Precautions (5.3)</a><span class="XmChange">]</span></span></span> </p>   <p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"> <span class="XmChange"><span class="Bold">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary <span class="Italics">[see <a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">Warnings and Precautions (5.3)</a>]</span>.</span></span> </p>   <p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"> <span class="XmChange"><span class="Bold">Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated <span class="Italics">[see <a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">Warnings and Precautions (5.3)</a>]</span>.</span></span> </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a> <div id="Highlights" class=" Highlights toggle-content closed">    <div class="HighlightsDisclaimer">   These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.   <br />    <br />ELIQUIS   <span class="Sup">&reg;</span> (apixaban) tablets for oral use   <br />Initial U.S. Approval: 2012  </div>   <div class="Warning">    <div>     <h1 class="Warning">WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS<br />(B) SPINAL/EPIDURAL HEMATOMA</h1>     <h1 class="Warning"> <span class="Italics">See full prescribing information for complete boxed warning.</span> </h1>     <p class="Highlighta"> <span class="Bold">(A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy. (<a href="#s2.5">2.5</a>, <a href="#ID_7b327732-537f-4c63-a4dd-2a41f437bc25">5.1</a>, <a href="#ID_a7613d0d-0fcb-40e6-9339-beecd55c7497">14.1</a>)</span> </p>     <p class="Highlighta"> <span class="Bold">(B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. <a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">(5.3)</a></span> </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>RECENT MAJOR CHANGES</span> </h1>    <div>     <p class="Highlighta"> <a href="#ID_4b7b5ac6-87a7-485a-b13e-6651b4b6e67f">Boxed Warning</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8/2014<br />Indications and Usage <a href="#ID_87e8f549-5689-49c7-a574-42a32ceb0c12">(1.2)</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3/2014<br />Indications and Usage (<a href="#ID_6feb5874-8796-407f-a183-0c18fc7b8cae">1.3</a>, <a href="#ID_4a536824-608b-49d7-b16d-3387bc2d5ddf">1.4</a>, <a href="#ID_6f624d78-06b4-48be-88a2-0b9f274516de">1.5</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8/2014<br />Dosage and Administration <a href="#s2.1">(2.1)</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8/2014<br />Dosage and Administration <a href="#ID_ad152d54-1c94-48c6-9890-9a35399e1157">(2.8)</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3/2014<br />Warnings and Precautions <a href="#ID_7b327732-537f-4c63-a4dd-2a41f437bc25">(5.1)</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8/2014<br />Warnings and Precautions <a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">(5.3)</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3/2014<br />Warnings and Precautions <a href="#ID_486900b3-4814-4606-8da8-2111894cacff">(5.5)</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8/2014 </p>    </div>   </div>   <div></div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>INDICATIONS AND USAGE</span> </h1>    <div>     <p class="Highlighta">ELIQUIS is a factor Xa inhibitor anticoagulant indicated: </p>     <dl>      <dt>      ●     </dt>      <dd>      to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.       <a href="#ID_748bf08c-1c39-4ef3-a127-67b6e147f799">(1.1)</a>      </dd>      <dt>      ●     </dt>      <dd>      for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.       <a href="#ID_87e8f549-5689-49c7-a574-42a32ceb0c12">(1.2)</a>      </dd>      <dt>      ●     </dt>      <dd>      for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (      <a href="#ID_6feb5874-8796-407f-a183-0c18fc7b8cae">1.3</a>,       <a href="#ID_4a536824-608b-49d7-b16d-3387bc2d5ddf">1.4</a>,       <a href="#ID_6f624d78-06b4-48be-88a2-0b9f274516de">1.5</a>)     </dd>     </dl>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE AND ADMINISTRATION</span> </h1>    <div>     <dl>      <dt>      ●     </dt>      <dd>      Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation:      <dl>        <dt>        ●       </dt>        <dd>        The recommended dose is 5 mg orally twice daily.         <a href="#s2.1">(2.1)</a>        </dd>        <dt>        ●       </dt>        <dd>        In patients with at least 2 of the following characteristics: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, the recommended dose is 2.5 mg orally twice daily.         <a href="#s2.2">(2.2)</a>        </dd>       </dl>      </dd>      <dt>      ●     </dt>      <dd>      Prophylaxis of DVT following hip or knee replacement surgery:      <dl>        <dt>        ●       </dt>        <dd>        The recommended dose is 2.5 mg orally twice daily.         <a href="#s2.1">(2.1)</a>        </dd>       </dl>      </dd>      <dt>      ●     </dt>      <dd>      Treatment of DVT and PE:      <dl>        <dt>        ●       </dt>        <dd>        The recommended dose is 10 mg taken orally twice daily for 7 days, followed by 5 mg taken orally twice daily.         <a href="#s2.1">(2.1)</a>        </dd>       </dl>      </dd>      <dt>      ●     </dt>      <dd>      Reduction in the risk of recurrent DVT and PE following initial therapy:      <dl>        <dt>        ●       </dt>        <dd>        The recommended dose is 2.5 mg taken orally twice daily.         <a href="#s2.1">(2.1)</a>        </dd>       </dl>      </dd>     </dl>    </div>    <div>     <div></div>     <div></div>     <div></div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE FORMS AND STRENGTHS</span> </h1>    <div>     <dl>      <dt>      ●     </dt>      <dd>      Tablets: 2.5 mg and 5 mg       <a href="#s3">(3)</a>      </dd>     </dl>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>CONTRAINDICATIONS</span> </h1>    <div>     <dl>      <dt>      ●     </dt>      <dd>      Active pathological bleeding       <a href="#s4">(4)</a>      </dd>      <dt>      ●     </dt>      <dd>      Severe hypersensitivity to ELIQUIS       <a href="#s4">(4)</a>      </dd>     </dl>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>WARNINGS AND PRECAUTIONS</span> </h1>    <div>     <dl>      <dt>      ●     </dt>      <dd>      ELIQUIS can cause serious, potentially fatal bleeding. Promptly evaluate signs and symptoms of blood loss.       <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">(5.2)</a>      </dd>      <dt>      ●     </dt>      <dd>      Prosthetic heart valves: ELIQUIS use not recommended.       <a href="#ID_540fc83f-54d6-41ec-bc04-c1b1831cd0e3">(5.4)</a>      </dd>     </dl>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>ADVERSE REACTIONS</span> </h1>    <div>     <p class="Highlighta">Most common adverse reactions (&gt;1%) are related to bleeding. <a href="#ID_e2e3f133-ee9c-4781-bcd7-3af1586e9ead">(6.1)</a> </p>     <p class="Highlighta"> <span class="Bold"> <br />To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or <span class="Italics"><span class="Underline">www.fda.gov/medwatch</span></span>.</span> </p>    </div>    <div>     <div>      <div></div>      <div></div>     </div>     <div></div>     <div>      <div></div>      <div></div>      <div></div>     </div>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DRUG INTERACTIONS</span> </h1>    <div>     <dl>      <dt>      ●     </dt>      <dd>      Strong dual inhibitors of CYP3A4 and P-gp increase blood levels of apixaban. Reduce dose or avoid coadministration.       <a href="#s2.2">(2.2</a>,       <a href="#ID_8e0aba69-393f-478b-b422-a499729c12a2">7.1</a>,       <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">12.3)</a>      </dd>      <dt>      ●     </dt>      <dd>      Simultaneous use of strong dual inducers of CYP3A4 and P-gp reduces blood levels of apixaban: Avoid concomitant use. (      <a href="#s2.2">2.2</a>,       <a href="#ID_8e0aba69-393f-478b-b422-a499729c12a2">7.2</a>,       <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">12.3</a>)     </dd>     </dl>    </div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>USE IN SPECIFIC POPULATIONS</span> </h1>    <div>     <dl>      <dt>      ●     </dt>      <dd>       <span class="Italics">Pregnancy:</span> Not recommended.       <a href="#ID_47163af8-a468-4113-acd7-e6f01f361d71">(8.1)</a>      </dd>      <dt>      ●     </dt>      <dd>       <span class="Italics">Nursing Mothers:</span> Discontinue drug or discontinue nursing.       <a href="#ID_49c34a2e-e9f2-40b3-94d0-9c14d350890b">(8.3)</a>      </dd>      <dt>      ●     </dt>      <dd>       <span class="Italics">Severe Hepatic Impairment:</span> Not recommended.       <a href="#ID_ffcee25e-6f0f-469c-84d4-4258bdd2d986">(12.2)</a>      </dd>     </dl>    </div>    <div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div></div>   <div>    <div></div>    <div>     <div></div>     <div></div>     <div></div>    </div>    <div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>    </div>   </div>   <div>    <div></div>   </div>   <div>    <div>     <div></div>     <div></div>    </div>    <div></div>    <div>     <div></div>     <div></div>    </div>   </div>   <div>    <div>     <div></div>    </div>    <div>     <div></div>    </div>   </div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>   <p class="HighlightsRevision">Revised: 8/2014</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a> <div id="Index" class=" Index toggle-content closed">    <h1> <a href="#section-1" class="toc"><span class="XmChange">WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS</span> <br /> <br /> <span class="XmChange">(B) SPINAL/EPIDURAL HEMATOMA</span></a> </h1>   <h1> <a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a> </h1>   <h2> <a href="#section-1.1" class="toc">1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation</a> </h2>   <h2> <a href="#section-1.2" class="toc"><span class="XmChange">1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery</span></a> </h2>   <h2> <a href="#section-1.3" class="toc"><span class="XmChange">1.3 Treatment of Deep Vein Thrombosis</span></a> </h2>   <h2> <a href="#section-1.4" class="toc"><span class="XmChange">1.4 Treatment of Pulmonary Embolism</span></a> </h2>   <h2> <a href="#section-1.5" class="toc"><span class="XmChange">1.5 Reduction in the Risk of Recurrence of DVT and PE</span></a> </h2>   <h1> <a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION </a> </h1>   <h2> <a href="#section-2.1" class="toc">2.1 Recommended Dose</a> </h2>   <h2> <a href="#section-2.2" class="toc">2.2 Dosage Adjustments</a> </h2>   <h2> <a href="#section-2.3" class="toc">2.3 Missed Dose</a> </h2>   <h2> <a href="#section-2.4" class="toc">2.4 Temporary Interruption for Surgery and Other Interventions</a> </h2>   <h2> <a href="#section-2.5" class="toc">2.5 Converting from or to ELIQUIS</a> </h2>   <h2> <a href="#section-2.6" class="toc">2.6 Hepatic Impairment</a> </h2>   <h2> <a href="#section-2.7" class="toc">2.7 Renal Impairment</a> </h2>   <h2> <a href="#section-2.8" class="toc"><span class="XmChange">2.8 Administration Options</span></a> </h2>   <h1> <a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a> </h1>   <h1> <a href="#section-4" class="toc">4 CONTRAINDICATIONS</a> </h1>   <h1> <a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a> </h1>   <h2> <a href="#section-5.1" class="toc"><span class="XmChange">5.1 Increased Risk of Thrombotic Events after Premature Discontinuation</span></a> </h2>   <h2> <a href="#section-5.2" class="toc">5.2 Bleeding</a> </h2>   <h2> <a href="#section-5.3" class="toc"><span class="XmChange">5.3 Spinal/Epidural Anesthesia or Puncture</span></a> </h2>   <h2> <a href="#section-5.4" class="toc">5.4 Patients with Prosthetic Heart Valves</a> </h2>   <h2> <a href="#section-5.5" class="toc"><span class="XmChange">5.5&nbsp;Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy</span></a> </h2>   <h1> <a href="#section-6" class="toc">6 ADVERSE REACTIONS</a> </h1>   <h2> <a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a> </h2>   <h1> <a href="#section-7" class="toc">7 DRUG INTERACTIONS</a> </h1>   <h2> <a href="#section-7.1" class="toc">7.1 Strong Dual Inhibitors of CYP3A4 and P-gp</a> </h2>   <h2> <a href="#section-7.2" class="toc">7.2 Strong Dual Inducers of CYP3A4 and P-gp</a> </h2>   <h2> <a href="#section-7.3" class="toc">7.3 Anticoagulants and Antiplatelet Agents</a> </h2>   <h1> <a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a> </h1>   <h2> <a href="#section-8.1" class="toc">8.1 Pregnancy</a> </h2>   <h2> <a href="#section-8.2" class="toc">8.2 Labor and Delivery</a> </h2>   <h2> <a href="#section-8.3" class="toc">8.3 Nursing Mothers</a> </h2>   <h2> <a href="#section-8.4" class="toc">8.4 Pediatric Use</a> </h2>   <h2> <a href="#section-8.5" class="toc">8.5 Geriatric Use</a> </h2>   <h2> <a href="#section-8.6" class="toc">8.6 End-Stage Renal Disease Patients Maintained with Hemodialysis</a> </h2>   <h1> <a href="#section-9" class="toc">10 OVERDOSAGE</a> </h1>   <h1> <a href="#section-10" class="toc">11 DESCRIPTION</a> </h1>   <h1> <a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a> </h1>   <h2> <a href="#section-11.1" class="toc">12.1 Mechanism of Action</a> </h2>   <h2> <a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a> </h2>   <h2> <a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a> </h2>   <h1> <a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a> </h1>   <h2> <a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a> </h2>   <h1> <a href="#section-13" class="toc">14 CLINICAL STUDIES</a> </h1>   <h2> <a href="#section-13.1" class="toc">14.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation</a> </h2>   <h2> <a href="#section-13.2" class="toc">14.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery</a> </h2>   <h2> <a href="#section-13.3" class="toc">14.3 Treatment of DVT and PE and Reduction in the Risk of Recurrence of DVT and PE</a> </h2>   <h1> <a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a> </h1>   <h1> <a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a> </h1>   <dl class="Footnote">    <dt>     <a name="footnote-content" href="#footnote-reference-content">*</a>    </dt>    <dd>    Sections or subsections omitted from the full prescribing information are not listed.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">1 INDICATIONS AND USAGE</a> <div class="Section toggle-content closed" data-sectioncode="34067-9">   <a name="s1"></a>  <a name="section-1"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="ID_748bf08c-1c39-4ef3-a127-67b6e147f799"></a>   <a name="section-1.1"></a>    <p></p>    <h2>1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation</h2>    <p class="First">ELIQUIS<span class="Sup">&reg;</span> (apixaban) is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_87e8f549-5689-49c7-a574-42a32ceb0c12"></a>   <a name="section-1.2"></a>    <p></p>    <h2 style="border-left:1px solid;"> <span class="XmChange">1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery</span> </h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_6feb5874-8796-407f-a183-0c18fc7b8cae"></a>   <a name="section-1.3"></a>    <p></p>    <h2 style="border-left:1px solid;"> <span class="XmChange">1.3 Treatment of Deep Vein Thrombosis</span> </h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">ELIQUIS is indicated for the treatment of DVT.</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_4a536824-608b-49d7-b16d-3387bc2d5ddf"></a>   <a name="section-1.4"></a>    <p></p>    <h2 style="border-left:1px solid;"> <span class="XmChange">1.4 Treatment of Pulmonary Embolism</span> </h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">ELIQUIS is indicated for the treatment of PE.</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_6f624d78-06b4-48be-88a2-0b9f274516de"></a>   <a name="section-1.5"></a>    <p></p>    <h2 style="border-left:1px solid;"> <span class="XmChange">1.5 Reduction in the Risk of Recurrence of DVT and PE</span> </h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy.</span> </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">2 DOSAGE AND ADMINISTRATION</a> <div class="Section toggle-content closed" data-sectioncode="34068-7">   <a name="s2"></a>  <a name="section-2"></a>   <p></p>    <div class="Section" data-sectioncode="34068-7">    <a name="s2.1"></a>   <a name="section-2.1"></a>    <p></p>    <h2>2.1 Recommended Dose</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_a0062d7d-22d4-4c56-835c-d9edba3c5785"></a>    <a name="section-2.1.1"></a>     <p></p>     <h3>Reduction of Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation</h3>     <p class="First">The recommended dose of ELIQUIS for most patients is 5 mg taken orally twice daily.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_c7a6f487-10d0-488f-996c-d7be67c46a0c"></a>    <a name="section-2.1.2"></a>     <p></p>     <h3 style="border-left:1px solid;"> <span class="XmChange">Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery</span> </h3>     <p class="First" style="border-left:1px solid;"> <span class="XmChange">The recommended dose of ELIQUIS is 2.5 mg taken orally twice daily. The initial dose should be taken 12 to 24 hours after surgery.</span> </p>     <dl>      <dt>      ●     </dt>      <dd>       <span class="XmChange">In patients undergoing hip replacement surgery, the recommended duration of treatment is 35 days.</span>      </dd>      <dt>      ●     </dt>      <dd>       <span class="XmChange">In patients undergoing knee replacement surgery, the recommended duration of treatment is 12 days.</span>      </dd>     </dl>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_c855ddea-1ab2-47c3-9fbb-a04a995ed1fd"></a>    <a name="section-2.1.3"></a>     <p></p>     <h3 style="border-left:1px solid;"> <span class="XmChange">Treatment of DVT and PE</span> </h3>     <p class="First" style="border-left:1px solid;"> <span class="XmChange">The recommended dose of ELIQUIS is 10 mg taken orally twice daily for 7 days, followed by 5&nbsp;mg taken orally twice daily.</span> </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_bf08e643-01cc-4c79-927c-9f3e988a0161"></a>    <a name="section-2.1.4"></a>     <p></p>     <h3 style="border-left:1px solid;"> <span class="XmChange">Reduction in the Risk of Recurrence of DVT and PE</span> </h3>     <p class="First" style="border-left:1px solid;"> <span class="XmChange">The recommended dose of ELIQUIS is 2.5 mg taken orally twice daily after at least 6 months of treatment for DVT or PE <span class="Italics">[see <a href="#ID_6fbc57af-782c-454d-9206-5ff789fe7c5b">Clinical Studies (14.3)</a>]</span>.</span> </p>    </div>   </div>   <div class="Section" data-sectioncode="34068-7">    <a name="s2.2"></a>   <a name="section-2.2"></a>    <p></p>    <h2>2.2 Dosage Adjustments</h2>    <p class="First"> <span class="Italics">In patients with nonvalvular atrial fibrillation:</span> The recommended dose of ELIQUIS is 2.5 mg twice daily in patients with any 2 of the following characteristics:</p>    <dl>     <dt>     ●    </dt>     <dd>     age ≥80 years    </dd>     <dt>     ●    </dt>     <dd>     body weight ≤60 kg    </dd>     <dt>     ●    </dt>     <dd>     serum creatinine ≥1.5 mg/dL    </dd>    </dl>    <p> <span class="Italics">Coadministration with strong dual CYP3A4 and P-gp inhibitors:</span> For patients receiving ELIQUIS doses greater than 2.5 mg twice daily, reduce the dose by 50% when ELIQUIS is coadministered with drugs that are strong dual inhibitors of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin) <span class="Italics">[see <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>.</p>    <p>In patients already taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with strong dual inhibitors of CYP3A4 and P-gp <span class="Italics">[see </span><span class="Italics"><a href="#ID_9dd32361-75eb-49c7-a5c9-f6ec6c14aef9">Drug Interactions (7.1)</a></span><span class="Italics">]</span>.</p>   </div>   <div class="Section" data-sectioncode="34068-7">    <a name="s2.3"></a>   <a name="section-2.3"></a>    <p></p>    <h2>2.3 Missed Dose</h2>    <p class="First">If a dose of ELIQUIS is not taken at the scheduled time, the dose should be taken as soon as possible on the same day and twice-daily administration should be resumed. The dose should not be doubled to make up for a missed dose.</p>   </div>   <div class="Section" data-sectioncode="34068-7">    <a name="s2.4"></a>   <a name="section-2.4"></a>    <p></p>    <h2>2.4 Temporary Interruption for Surgery and Other Interventions</h2>    <p class="First">ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be non-critical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established.</p>   </div>   <div class="Section" data-sectioncode="34068-7">    <a name="s2.5"></a>   <a name="section-2.5"></a>    <p></p>    <h2>2.5 Converting from or to ELIQUIS</h2>    <p class="First"> <span class="Italics">Switching from warfarin to ELIQUIS:</span> Warfarin should be discontinued and ELIQUIS started when the international normalized ratio (INR) is below 2.0.</p>    <p> <span class="Italics">Switching from ELIQUIS to warfarin:</span> ELIQUIS affects INR, so that initial INR measurements during the transition to warfarin may not be useful for determining the appropriate dose of warfarin. If continuous anticoagulation is necessary, discontinue ELIQUIS and begin both a parenteral anticoagulant and warfarin at the time the next dose of ELIQUIS would have been taken, discontinuing the parenteral anticoagulant when INR reaches an acceptable range.</p>    <p> <span class="Italics">Switching between ELIQUIS and anticoagulants other than warfarin:</span> Discontinue one being taken and begin the other at the next scheduled dose.</p>   </div>   <div class="Section" data-sectioncode="34068-7">    <a name="s2.6"></a>   <a name="section-2.6"></a>    <p></p>    <h2>2.6 Hepatic Impairment</h2>    <p class="First">No dose adjustment is required in patients with mild hepatic impairment.</p>    <p>Because patients with moderate hepatic impairment may have intrinsic coagulation abnormalities and there is limited clinical experience with ELIQUIS in these patients, dosing recommendations cannot be provided <span class="Italics">[see <a href="#ID_ffcee25e-6f0f-469c-84d4-4258bdd2d986">Clinical Pharmacology (12.2)</a>]</span>.</p>    <p>ELIQUIS is not recommended in patients with severe hepatic impairment <span class="Italics">[see <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="34068-7">    <a name="s2.7"></a>   <a name="section-2.7"></a>    <p></p>    <h2>2.7 Renal Impairment</h2>    <p class="First">The dosing adjustment for patients with moderate renal impairment and nonvalvular atrial fibrillation is described above <span class="Italics">[see <a href="#s2.2">Dosage and Administration (2.2)</a>]</span>. The recommended dose for nonvalvular atrial fibrillation patients with end-stage renal disease (ESRD) maintained on hemodialysis is 5 mg twice daily. Reduce dose to 2.5 mg twice daily if one of the following patient characteristics (age ≥80 years or body weight ≤60 kg) is present <span class="Italics">[see <a href="#ID_08b58613-14d0-431e-bbd5-fc25b4e4026f">Use in Specific Populations (8.6)</a> and <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>.</p>    <p>No dose adjustment is required for the following indications:</p>    <dl>     <dt>     ●    </dt>     <dd>     for the prophylaxis of DVT, which may lead to PE, in patients who have undergone hip or knee replacement surgery.    </dd>     <dt>     ●    </dt>     <dd>     for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE.    </dd>    </dl>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_ad152d54-1c94-48c6-9890-9a35399e1157"></a>   <a name="section-2.8"></a>    <p></p>    <h2 style="border-left:1px solid;"> <span class="XmChange">2.8 Administration Options</span> </h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">For patients who are unable to swallow whole tablets, 5 mg and 2.5 mg ELIQUIS tablets may be crushed and suspended in 60 mL D5W and immediately delivered through a nasogastric tube (NGT) <span class="Italics">[see <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>. Information regarding the administration of crushed and suspended ELIQUIS tablets swallowed by mouth is not available.</span> </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a> <div class="Section toggle-content closed" data-sectioncode="43678-2">   <a name="s3"></a>  <a name="section-3"></a>   <p></p>    <dl>    <dt>    ●   </dt>    <dd>    2.5 mg, yellow, round, biconvex, film-coated tablets with “893” debossed on one side and “2&frac12;” on the other side.   </dd>    <dt>    ●   </dt>    <dd>    5 mg, pink, oval-shaped, biconvex, film-coated tablets with “894” debossed on one side and “5” on the other side.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">4 CONTRAINDICATIONS</a> <div class="Section toggle-content closed" data-sectioncode="34070-3">   <a name="s4"></a>  <a name="section-4"></a>   <p></p>    <p class="First">ELIQUIS is contraindicated in patients with the following conditions:</p>   <dl>    <dt>    ●   </dt>    <dd>    Active pathological bleeding     <span class="Italics">[see <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">Warnings and Precautions (5.2)</a> and <a href="#ID_e2e3f133-ee9c-4781-bcd7-3af1586e9ead">Adverse Reactions (6.1)</a>]</span>    </dd>    <dt>    ●   </dt>    <dd>    Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions)     <span class="Italics">[see <a href="#ID_e2e3f133-ee9c-4781-bcd7-3af1586e9ead">Adverse Reactions (6.1)</a>]</span>    </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">5 WARNINGS AND PRECAUTIONS</a> <div class="Section toggle-content closed" data-sectioncode="43685-7">   <a name="s5"></a>  <a name="section-5"></a>   <p></p>    <div class="Section" data-sectioncode="43685-7">    <a name="ID_7b327732-537f-4c63-a4dd-2a41f437bc25"></a>   <a name="section-5.1"></a>    <p></p>    <h2 style="border-left:1px solid;"> <span class="XmChange">5.1 Increased Risk of Thrombotic Events after Premature Discontinuation</span> </h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant <span class="Italics">[see <a href="#s2.5">Dosage and Administration (2.5)</a> and <a href="#ID_a7613d0d-0fcb-40e6-9339-beecd55c7497">Clinical Studies (14.1)</a>]</span>.</span> </p>   </div>   <div class="Section" data-sectioncode="43685-7">    <a name="ID_b926cbc1-03a8-457d-a907-48ea48aba809"></a>   <a name="section-5.2"></a>    <p></p>    <h2>5.2 Bleeding</h2>    <p class="First">ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding <span class="Italics">[see <a href="#s2.2">Dosage and Administration (2.2)</a> and <a href="#ID_e2e3f133-ee9c-4781-bcd7-3af1586e9ead">Adverse Reactions (6.1)</a>]</span>.</p>    <p>Concomitant use of drugs affecting hemostasis increases the risk of bleeding. These include aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and nonsteroidal anti-inflammatory drugs (NSAIDs) <span class="Italics">[see <a href="#ID_db976135-f7e4-4774-b901-842930552cf7">Drug Interactions (7.3)</a>]</span>.</p>    <p>Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage.</p>    <p>There is no established way to reverse the anticoagulant effect of apixaban, which can be expected to persist for at least 24 hours after the last dose, i.e., for about two drug half-lives. A specific antidote for ELIQUIS is not available. Hemodialysis does not appear to have a substantial impact on apixaban exposure <span class="Italics">[see <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban. There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving apixaban. There is neither scientific rationale for reversal nor experience with systemic hemostatics (desmopressin and aprotinin) in individuals receiving apixaban. Use of procoagulant reversal agents such as prothrombin complex concentrate, activated prothrombin complex concentrate, or recombinant factor VIIa may be considered but has not been evaluated in clinical studies. Activated oral charcoal reduces absorption of apixaban, thereby lowering apixaban plasma concentration <span class="Italics">[see <a href="#s10">Overdosage (10)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e"></a>   <a name="section-5.3"></a>    <p></p>    <h2 style="border-left:1px solid;"> <span class="XmChange">5.3 Spinal/Epidural Anesthesia or Puncture</span> </h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.</span> </p>    <p style="border-left:1px solid;"> <span class="XmChange">The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours.</span> </p>    <p style="border-left:1px solid;"> <span class="XmChange">Monitor patients frequently for signs and symptoms of neurological impairment (e.g., numbness or weakness of the legs, bowel, or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis.</span> </p>   </div>   <div class="Section" data-sectioncode="43685-7">    <a name="ID_540fc83f-54d6-41ec-bc04-c1b1831cd0e3"></a>   <a name="section-5.4"></a>    <p></p>    <h2>5.4 Patients with Prosthetic Heart Valves</h2>    <p class="First">The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves. Therefore, use of ELIQUIS is not recommended in these patients.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_486900b3-4814-4606-8da8-2111894cacff"></a>   <a name="section-5.5"></a>    <p></p>    <h2 style="border-left:1px solid;"> <span class="XmChange">5.5&nbsp;Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy</span> </h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">Initiation of ELIQUIS is not recommended as an alternative to unfractionated heparin for the initial treatment of patients with PE who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.</span> </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">6 ADVERSE REACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34084-4">   <a name="s6"></a>  <a name="section-6"></a>   <p></p>    <p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information.</p>   <dl>    <dt>    ●   </dt>    <dd>    Increased risk of thrombotic events after premature discontinuation     <span class="Italics">[see <a href="#ID_7b327732-537f-4c63-a4dd-2a41f437bc25">Warnings and Precautions (5.1)</a>]</span>    </dd>    <dt>    ●   </dt>    <dd>    Bleeding     <span class="Italics">[see <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">Warnings and Precautions (5.2)</a>]</span>    </dd>    <dt>    ●   </dt>    <dd>    Spinal/epidural anesthesia or puncture     <span class="Italics">[see <a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">Warnings and Precautions (5.3)</a>]</span>    </dd>   </dl>   <div class="Section" data-sectioncode="34084-4">    <a name="ID_e2e3f133-ee9c-4781-bcd7-3af1586e9ead"></a>   <a name="section-6.1"></a>    <p></p>    <h2>6.1 Clinical Trials Experience</h2>    <p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>    <p></p>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_fb7e3c59-041f-45be-81a1-f6d6724d3617"></a>    <a name="section-6.1.1"></a>     <p></p>     <h3>Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation</h3>     <p class="First">The safety of ELIQUIS was evaluated in the ARISTOTLE and AVERROES studies <span class="Italics">[see <a href="#s14">Clinical Studies (14)</a>]</span>, including 11,284 patients exposed to ELIQUIS 5 mg twice daily and 602 patients exposed to ELIQUIS 2.5 mg twice daily. The duration of ELIQUIS exposure was ≥12 months for 9375 patients and ≥24 months for 3369 patients in the two studies. In ARISTOTLE, the mean duration of exposure was 89 weeks (&gt;15,000 patient-years). In AVERROES, the mean duration of exposure was approximately 59 weeks (&gt;3000 patient-years).</p>     <p>The most common reason for treatment discontinuation in both studies was for bleeding-related adverse reactions; in ARISTOTLE this occurred in 1.7% and 2.5% of patients treated with ELIQUIS and warfarin, respectively, and in AVERROES, in 1.5% and 1.3% on ELIQUIS and aspirin, respectively.</p>     <div class="Section" data-sectioncode="34084-4">      <a name="ID_943d572f-8a88-4111-8007-366bc830d096"></a>     <a name="section-6.1.1.1"></a>      <p></p>      <h4>Bleeding in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE and AVERROES</h4>      <p class="First">Tables 1 and 2 show the number of patients experiencing major bleeding during the treatment period and the bleeding rate (percentage of subjects with at least one bleeding event per year) in ARISTOTLE and AVERROES.</p>      <p> <span class="Italics">Major bleeding</span> was defined as clinically overt bleeding that was accompanied by one or more of the following: a decrease in hemoglobin of 2 g/dL or more; a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least one of the following critical sites: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; or bleeding that was fatal. Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.</p>      <div class="scrollingtable">      <table>        <caption>         <span>Table 1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bleeding Events in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE</span>        </caption>        <colgroup>        <col width="29%" />         <col width="23%" />         <col width="23%" />         <col width="23%" />         <col width="17%" />        </colgroup>       <thead>         <tr class="First Last">          <th class="Botrule Toprule" valign="top"></th>         <th class="Botrule Toprule" valign="top">ELIQUIS<br />N=9088<br />n (%/year)</th>         <th class="Botrule Toprule" valign="top">Warfarin<br />N=9052<br />n (%/year)</th>         <th class="Botrule Toprule" valign="top">Hazard Ratio<br />(95% CI*)</th>         <th class="Botrule Toprule" valign="top">P-value</th>         </tr>        </thead>        <tfoot>         <tr class="First Last">          <td class="Botrule" align="left" colspan="5" valign="top">*&nbsp;&nbsp;Confidence interval.<br /> <span class="Sup">†</span>&nbsp;&nbsp;&nbsp;International Society on Thrombosis and Hemostasis (ISTH) major bleed assessed by sequential testing strategy for superiority designed to control the overall type I error in the trial.<br /> <span class="Sup">‡</span>&nbsp;&nbsp;&nbsp;GI bleed includes upper GI, lower GI, and rectal bleeding.<br /> <span class="Sup">&sect;</span>&nbsp;&nbsp;&nbsp;Intraocular bleed is within the corpus of the eye (a conjunctival bleed is not an intraocular bleed).<br /> <span class="Sup">&para;</span>&nbsp;&nbsp;&nbsp;Fatal bleed is an adjudicated death because of bleeding during the treatment period and includes both fatal extracranial bleeds and fatal hemorrhagic stroke.<br />**&nbsp;CRNM = clinically relevant nonmajor bleeding.<br />Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.</td>         </tr>        </tfoot>        <tbody>         <tr class="First">          <td class="Toprule"> <p class="First">Major<span class="Sup">†</span> </p> </td>         <td class="Toprule" align="center"> <p class="First">327 (2.13)</p> </td>         <td class="Toprule" align="center"> <p class="First">462 (3.09)</p> </td>         <td class="Toprule" align="center"> <p class="First">0.69 (0.60, 0.80)</p> </td>         <td class="Toprule" align="center"> <p class="First">&lt;0.0001</p> </td>         </tr>         <tr>          <td> <p class="First">&nbsp;&nbsp;&nbsp;&nbsp;Gastrointestinal (GI)<span class="Sup">‡</span> </p> </td>         <td align="center"> <p class="First">128 (0.83)</p> </td>         <td align="center"> <p class="First">141 (0.93)</p> </td>         <td align="center"> <p class="First">0.89 (0.70, 1.14)</p> </td>         <td align="center"> <p class="First">-</p> </td>         </tr>         <tr>          <td> <p class="First">&nbsp;&nbsp;&nbsp;&nbsp;Intracranial</p> </td>         <td align="center"> <p class="First">52 (0.33)</p> </td>         <td align="center"> <p class="First">125 (0.82)</p> </td>         <td align="center"> <p class="First">0.41 (0.30, 0.57)</p> </td>         <td align="center"> <p class="First">-</p> </td>         </tr>         <tr>          <td> <p class="First">&nbsp;&nbsp;&nbsp;&nbsp;Intraocular<span class="Sup">&sect;</span> </p> </td>         <td align="center"> <p class="First">32 (0.21)</p> </td>         <td align="center"> <p class="First">22 (0.14)</p> </td>         <td align="center"> <p class="First">1.42 (0.83, 2.45)</p> </td>         <td align="center"> <p class="First">-</p> </td>         </tr>         <tr>          <td> <p class="First">&nbsp;&nbsp;&nbsp;&nbsp;Fatal<span class="Sup">&para;</span> </p> </td>         <td align="center"> <p class="First">10 (0.06)</p> </td>         <td align="center"> <p class="First">37 (0.24)</p> </td>         <td align="center"> <p class="First">0.27 (0.13, 0.53)</p> </td>         <td align="center"> <p class="First">-</p> </td>         </tr>         <tr class="Last">          <td class="Botrule"> <p class="First">CRNM**</p> </td>         <td class="Botrule" align="center"> <p class="First">318 (2.08)</p> </td>         <td class="Botrule" align="center"> <p class="First">444 (3.00)</p> </td>         <td class="Botrule" align="center"> <p class="First">0.70 (0.60, 0.80)</p> </td>         <td class="Botrule" align="center"> <p class="First">&lt;0.0001</p> </td>         </tr>        </tbody>       </table>     </div>      <p>In ARISTOTLE, the results for major bleeding were generally consistent across most major subgroups including age, weight, CHADS<span class="Sub">2</span> score (a scale from 0 to 6 used to estimate risk of stroke, with higher scores predicting greater risk), prior warfarin use, geographic region, ELIQUIS dose, type of atrial fibrillation (AF), and aspirin use at randomization (Figure 1). Subjects treated with apixaban with diabetes bled more (3.0% per year) than did subjects without diabetes (1.9% per year).</p>      <p>Figure <a href="#">1</a>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Major Bleeding Hazard Ratios by Baseline Characteristics – ARISTOTLE Study</p>      <div class="Figure">       <a name="id15689367"></a>      <img src="image.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0&name=eliquis%2Dforest%2Dfig1%2Ejpg" alt="ARISTOTLE Major Bleeding Forest Plot" />     </div>      <p></p>      <div class="scrollingtable">      <table>        <caption>         <span>Table 2: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bleeding Events in Patients with Nonvalvular Atrial Fibrillation in AVERROES</span>        </caption>        <colgroup>        <col width="29%" />         <col width="23%" />         <col width="23%" />         <col width="23%" />         <col width="17%" />        </colgroup>       <thead>         <tr class="First Last">          <th class="Botrule Toprule" valign="top"></th>         <th class="Botrule Toprule" valign="top">ELIQUIS<br />N=2798<br />n (%/year)</th>         <th class="Botrule Toprule" valign="top">Aspirin<br />N=2780<br />n (%/year)</th>         <th class="Botrule Toprule" valign="top">Hazard Ratio<br />(95% CI)</th>         <th class="Botrule Toprule" valign="top">P-value</th>         </tr>        </thead>        <tfoot>         <tr class="First Last">          <td class="Botrule" align="left" colspan="10" valign="top">Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.</td>         </tr>        </tfoot>        <tbody>         <tr class="First">          <td class="Toprule"> <p class="First">Major</p> </td>         <td class="Toprule" align="center"> <p class="First">45 (1.41)</p> </td>         <td class="Toprule" align="center"> <p class="First">29 (0.92)</p> </td>         <td class="Toprule" align="center"> <p class="First">1.54 (0.96, 2.45)</p> </td>         <td class="Toprule" align="center"> <p class="First">0.07</p> </td>         </tr>         <tr>          <td> <p class="First">&nbsp;&nbsp;&nbsp;&nbsp;Fatal</p> </td>         <td align="center"> <p class="First">5 (0.16)</p> </td>         <td align="center"> <p class="First">5 (0.16)</p> </td>         <td align="center"> <p class="First">0.99 (0.23, 4.29)</p> </td>         <td align="center"> <p class="First">-</p> </td>         </tr>         <tr class="Last">          <td class="Botrule"> <p class="First">&nbsp;&nbsp;&nbsp;&nbsp;Intracranial</p> </td>         <td class="Botrule" align="center"> <p class="First">11 (0.34)</p> </td>         <td class="Botrule" align="center"> <p class="First">11 (0.35)</p> </td>         <td class="Botrule" align="center"> <p class="First">0.99 (0.39, 2.51)</p> </td>         <td class="Botrule" align="center"> <p class="First">-</p> </td>         </tr>        </tbody>       </table>     </div>     </div>     <div class="Section" data-sectioncode="34084-4">      <a name="ID_e1d9695c-0bf3-420a-b1ee-34ac719f2c7d"></a>     <a name="section-6.1.1.2"></a>      <p></p>      <h4>Other Adverse Reactions</h4>      <p class="First">Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in &lt;1% of patients receiving ELIQUIS.</p>     </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_72af8d8f-3b4e-4258-8836-bd0e77435d4a"></a>    <a name="section-6.1.2"></a>     <p></p>     <h3>Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery</h3>     <p class="First">The safety of ELIQUIS has been evaluated in 1 Phase II and 3 Phase III studies including 5924 patients exposed to ELIQUIS 2.5 mg twice daily undergoing major orthopedic surgery of the lower limbs (elective hip replacement or elective knee replacement) treated for up to 38 days.</p>     <p>In total, 11% of the patients treated with ELIQUIS 2.5 mg twice daily experienced adverse reactions.</p>     <p>Bleeding results during the treatment period in the Phase III studies are shown in Table 3. Bleeding was assessed in each study beginning with the first dose of double-blind study drug.</p>     <div class="scrollingtable">     <table>       <caption>        <span>Table 3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bleeding During the Treatment Period in Patients Undergoing Elective Hip or Knee Replacement Surgery</span>       </caption>       <colgroup>       <col width="16%" />        <col width="17%" />        <col width="16%" />        <col width="17%" />        <col width="15%" />        <col width="17%" />        <col width="17%" />       </colgroup>      <thead>        <tr class="First Last">         <th class="Botrule Rrule Toprule" valign="top"><span class="Bold">Bleeding Endpoint*</span></th>        <th class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><span class="Bold">ADVANCE-3<br />Hip Replacement Surgery</span></th>        <th class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><span class="Bold">ADVANCE-2<br />Knee Replacement Surgery</span></th>        <th class="Botrule Lrule Toprule" colspan="2" valign="top"><span class="Bold">ADVANCE-1<br />Knee Replacement Surgery</span></th>        </tr>       </thead>       <tfoot>        <tr class="First Last">         <td class="Botrule" align="left" colspan="7" valign="top">*&nbsp;&nbsp;&nbsp;All bleeding criteria included surgical site bleeding.<br /> <span class="Sup">†</span>&nbsp;&nbsp;&nbsp;Includes 13 subjects with major bleeding events that occurred before the first dose of apixaban (administered 12 to 24 hours post surgery).<br /> <span class="Sup">‡</span>&nbsp;&nbsp;&nbsp;Includes 5 subjects with major bleeding events that occurred before the first dose of apixaban (administered 12 to 24 hours post surgery).<br /> <span class="Sup">&sect;</span>&nbsp;&nbsp;&nbsp;Intracranial, intraspinal, intraocular, pericardial, an operated joint requiring re-operation or intervention, intramuscular with compartment syndrome, or retroperitoneal. Bleeding into an operated joint requiring re-operation or intervention was present in all patients with this category of bleeding. Events and event rates include one enoxaparin-treated patient in ADVANCE-1 who also had intracranial hemorrhage.<br /> <span class="Sup">&para;</span>&nbsp;&nbsp;&nbsp;CRNM = clinically relevant nonmajor.</td>        </tr>       </tfoot>       <tbody>        <tr class="First">         <td class="Rrule Toprule" rowspan="2"></td>        <td class="Lrule Rrule Toprule" align="center"> <p class="First">ELIQUIS<br />2.5 mg po bid<br />35&plusmn;3 days</p> </td>        <td class="Lrule Rrule Toprule" align="center"> <p class="First">Enoxaparin <br />40 mg sc qd <br />35&plusmn;3 days</p> </td>        <td class="Lrule Rrule Toprule" align="center"> <p class="First">ELIQUIS <br />2.5 mg po bid <br />12&plusmn;2 days</p> </td>        <td class="Lrule Rrule Toprule" align="center"> <p class="First">Enoxaparin <br />40 mg sc qd <br />12&plusmn;2 days</p> </td>        <td class="Lrule Rrule Toprule" align="center"> <p class="First">ELIQUIS <br />2.5 mg po bid <br />12&plusmn;2 days</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">Enoxaparin <br />30 mg sc q12h 12&plusmn;2 days</p> </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">First dose <br />12 to 24 hours post surgery</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">First dose <br />9 to 15 hours prior to surgery</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">First dose <br />12 to 24 hours post surgery</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">First dose <br />9 to 15 hours prior to surgery</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">First dose <br />12 to 24 hours post surgery</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">First dose <br />12 to 24 hours post surgery</p> </td>        </tr>        <tr>         <td class="Botrule Rrule Toprule"> <p class="First">All treated</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">N=2673</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">N=2659</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">N=1501</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">N=1508</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">N=1596</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">N=1588</p> </td>        </tr>        <tr>         <td class="Botrule Rrule Toprule"> <p class="First">Major (including surgical site)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">22 (0.82%)<span class="Sup">†</span> </p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">18 (0.68%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">9 (0.60%)<span class="Sup">‡</span> </p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">14 (0.93%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">11 (0.69%)</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">22 (1.39%)</p> </td>        </tr>        <tr>         <td class="Botrule Rrule Toprule"> <p class="First">&nbsp;&nbsp;Fatal</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">0</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">0</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">0</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">0</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">0</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">1 (0.06%)</p> </td>        </tr>        <tr>         <td class="Botrule Rrule Toprule"> <p class="First">&nbsp;&nbsp;Hgb decrease ≥2&nbsp;g/dL</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">13 (0.49%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">10 (0.38%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">8 (0.53%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">9 (0.60%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">10 (0.63%)</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">16 (1.01%)</p> </td>        </tr>        <tr>         <td class="Botrule Rrule Toprule"> <p class="First">&nbsp;&nbsp;Transfusion of ≥2 units RBC</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">16 (0.60%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">14 (0.53%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">5 (0.33%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">9 (0.60%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">9 (0.56%)</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">18 (1.13%)</p> </td>        </tr>        <tr>         <td class="Botrule Rrule Toprule"> <p class="First">&nbsp;&nbsp;Bleed at critical site<span class="Sup">&sect;</span> </p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">1 (0.04%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">1 (0.04%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">1 (0.07%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">2 (0.13%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">1 (0.06%)</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">4 (0.25%)</p> </td>        </tr>        <tr>         <td class="Botrule Rrule Toprule"> <p class="First">Major<br />+ CRNM<span class="Sup">&para;</span> </p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">129 (4.83%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">134 (5.04%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">53 (3.53%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">72 (4.77%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">46 (2.88%)</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">68 (4.28%)</p> </td>        </tr>        <tr class="Last">         <td class="Botrule Rrule Toprule"> <p class="First">All</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">313 (11.71%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">334 (12.56%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">104 (6.93%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">126 (8.36%)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">85 (5.33%)</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">108 (6.80%)</p> </td>        </tr>       </tbody>      </table>    </div>     <p>Adverse reactions occurring in ≥1% of patients undergoing hip or knee replacement surgery in the 1 Phase II study and the 3 Phase III studies are listed in Table 4.</p>     <div class="scrollingtable">     <table>       <caption>        <span>Table 4:&nbsp;&nbsp;&nbsp; &nbsp;Adverse Reactions Occurring in ≥1% of Patients in Either Group Undergoing Hip or Knee Replacement Surgery</span>       </caption>       <colgroup>       <col width="64%" />        <col width="23%" />        <col width="29%" />       </colgroup>      <thead>        <tr class="First Last">         <th class="Botrule Rrule Toprule" valign="top"></th>        <th class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">ELIQUIS, n (%) <br />2.5 mg po bid <br /> <br />N=5924</span></th>        <th class="Botrule Lrule Toprule" valign="top"><span class="Bold">Enoxaparin, n (%) <br />40 mg sc qd or <br />30 mg sc q12h <br />N=5904</span></th>        </tr>       </thead>       <tbody>        <tr class="First">         <td class="Botrule Rrule Toprule"> <p class="First">Nausea</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">153 (2.6)</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">159 (2.7)</p> </td>        </tr>        <tr>         <td class="Botrule Rrule Toprule"> <p class="First">Anemia (including postoperative and hemorrhagic anemia, and respective laboratory parameters)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">153 (2.6)</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">178 (3.0)</p> </td>        </tr>        <tr>         <td class="Botrule Rrule Toprule"> <p class="First">Contusion</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">83 (1.4)</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">115 (1.9)</p> </td>        </tr>        <tr>         <td class="Botrule Rrule Toprule"> <p class="First">Hemorrhage (including hematoma, and vaginal and urethral hemorrhage)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">67 (1.1)</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">81 (1.4)</p> </td>        </tr>        <tr>         <td class="Botrule Rrule Toprule"> <p class="First">Postprocedural hemorrhage (including postprocedural hematoma, wound hemorrhage, vessel puncture site hematoma and catheter site hemorrhage)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">54 (0.9)</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">60 (1.0)</p> </td>        </tr>        <tr>         <td class="Botrule Rrule Toprule"> <p class="First">Transaminases increased (including alanine aminotransferase increased and alanine aminotransferase abnormal)</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">50 (0.8)</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">71 (1.2)</p> </td>        </tr>        <tr>         <td class="Botrule Rrule Toprule"> <p class="First">Aspartate aminotransferase increased</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">47 (0.8)</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">69 (1.2)</p> </td>        </tr>        <tr class="Last">         <td class="Botrule Rrule Toprule"> <p class="First">Gamma-glutamyltransferase increased</p> </td>        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">38 (0.6)</p> </td>        <td class="Botrule Lrule Toprule" align="center"> <p class="First">65 (1.1)</p> </td>        </tr>       </tbody>      </table>    </div>     <p>Less common adverse reactions in apixaban-treated patients undergoing hip or knee replacement surgery occurring at a frequency of ≥0.1% to &lt;1%:</p>     <p> <span class="Italics">Blood and lymphatic system disorders:</span> thrombocytopenia (including platelet count decreases)</p>     <p> <span class="Italics">Vascular disorders:</span> hypotension (including procedural hypotension)</p>     <p> <span class="Italics">Respiratory, thoracic, and mediastinal disorders:</span> epistaxis</p>     <p> <span class="Italics">Gastrointestinal disorders:</span> gastrointestinal hemorrhage (including hematemesis and melena), hematochezia</p>     <p> <span class="Italics">Hepatobiliary disorders:</span> liver function test abnormal, blood alkaline phosphatase increased, blood bilirubin increased</p>     <p> <span class="Italics">Renal and urinary disorders:</span> hematuria (including respective laboratory parameters)</p>     <p> <span class="Italics">Injury, poisoning, and procedural complications:</span> wound secretion, incision-site hemorrhage (including incision-site hematoma), operative hemorrhage</p>     <p>Less common adverse reactions in apixaban-treated patients undergoing hip or knee replacement surgery occurring at a frequency of &lt;0.1%:</p>     <p>Gingival bleeding, hemoptysis, hypersensitivity, muscle hemorrhage, ocular hemorrhage (including conjunctival hemorrhage), rectal hemorrhage</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_75a2c4e9-34d0-420b-bb27-396a6aea58a1"></a>    <a name="section-6.1.3"></a>     <p></p>     <h3>Treatment of DVT and PE and Reduction in the Risk of Recurrence of DVT or PE</h3>     <p class="First">The safety of ELIQUIS has been evaluated in the AMPLIFY and AMPLIFY-EXT studies, including 2676 patients exposed to ELIQUIS 10 mg twice daily, 3359 patients exposed to ELIQUIS 5 mg twice daily, and 840 patients exposed to ELIQUIS 2.5 mg twice daily.</p>     <p>Common adverse reactions (≥1%) were gingival bleeding, epistaxis, contusion, hematuria, rectal hemorrhage, hematoma, menorrhagia, and hemoptysis.</p>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_a3997a8b-697a-44f3-9ef3-f14efa442fe5"></a>     <a name="section-6.1.3.1"></a>      <p></p>      <h4>AMPLIFY Study</h4>      <p class="First">The mean duration of exposure to ELIQUIS was 154 days and to enoxaparin/warfarin was 152 days in the AMPLIFY study. Adverse reactions related to bleeding occurred in 417 (15.6%) ELIQUIS-treated patients compared to 661 (24.6%) enoxaparin/warfarin-treated patients. The discontinuation rate due to bleeding events was 0.7% in the ELIQUIS-treated patients compared to 1.7% in enoxaparin/warfarin-treated patients in the AMPLIFY study.</p>      <p>In the AMPLIFY study, ELIQUIS was statistically superior to enoxaparin/warfarin in the primary safety endpoint of major bleeding (relative risk 0.31, 95% CI [0.17, 0.55], P-value &lt;0.0001).</p>      <p>Bleeding results from the AMPLIFY study are summarized in Table 5.</p>      <div class="scrollingtable">      <table>        <caption>         <span>Table 5:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bleeding Results in the AMPLIFY Study</span>        </caption>        <colgroup>        <col width="23%" />         <col width="23%" />         <col width="29%" />         <col width="40%" />        </colgroup>       <thead>         <tr class="First Last">          <th class="Botrule Toprule" valign="top"></th>         <th class="Botrule Toprule" valign="top">ELIQUIS <br />N=2676<br />n (%)</th>         <th class="Botrule Toprule" valign="top">Enoxaparin/Warfarin<br />N=2689<br />n (%)</th>         <th class="Botrule Toprule" valign="top">Relative Risk (95% CI)</th>         </tr>        </thead>        <tfoot>         <tr class="First Last">          <td class="Botrule" align="left" colspan="4" valign="top">*&nbsp;&nbsp;&nbsp;CRNM = clinically relevant nonmajor bleeding.<br />Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.</td>         </tr>        </tfoot>        <tbody>         <tr class="First">          <td class="Toprule"> <p class="First">Major</p> </td>         <td align="center"> <p class="First">15 (0.6)</p> </td>         <td align="center"> <p class="First">49 (1.8)</p> </td>         <td align="center"> <p class="First">0.31 (0.17, 0.55)<br />p&lt;0.0001</p> </td>         </tr>         <tr>          <td> <p class="First">CRNM*</p> </td>         <td align="center"> <p class="First">103 (3.9)</p> </td>         <td align="center"> <p class="First">215 (8.0)</p> </td>         <td></td>         </tr>         <tr>          <td> <p class="First">Major + CRNM</p> </td>         <td align="center"> <p class="First">115 (4.3)</p> </td>         <td align="center"> <p class="First">261 (9.7)</p> </td>         <td></td>         </tr>         <tr>          <td> <p class="First">Minor</p> </td>         <td align="center"> <p class="First">313 (11.7)</p> </td>         <td align="center"> <p class="First">505 (18.8)</p> </td>         <td></td>         </tr>         <tr class="Last">          <td class="Botrule"> <p class="First">All</p> </td>         <td class="Botrule" align="center"> <p class="First">402 (15.0)</p> </td>         <td class="Botrule" align="center"> <p class="First">676 (25.1)</p> </td>         <td class="Botrule"></td>         </tr>        </tbody>       </table>     </div>      <p>Adverse reactions occurring in ≥1% of patients in the AMPLIFY study are listed in Table 6.</p>      <div class="scrollingtable">      <table>        <caption>         <span>Table 6:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adverse Reactions Occurring in ≥1% of Patients Treated for DVT and PE in the AMPLIFY Study</span>        </caption>        <colgroup>        <col width="38%" />         <col width="38%" />         <col width="38%" />        </colgroup>       <thead>         <tr class="First Last">          <th class="Botrule Toprule" valign="top"></th>         <th class="Botrule Toprule" valign="top">ELIQUIS <br />N=2676 <br />n (%)</th>         <th class="Botrule Toprule" valign="top">Enoxaparin/Warfarin <br />N=2689 <br />n (%)</th>         </tr>        </thead>        <tbody>         <tr class="First">          <td class="Toprule"> <p class="First">Epistaxis</p> </td>         <td class="Toprule" align="center"> <p class="First">77 (2.9)</p> </td>         <td class="Toprule" align="center"> <p class="First">146 (5.4)</p> </td>         </tr>         <tr>          <td> <p class="First">Contusion</p> </td>         <td align="center"> <p class="First">49 (1.8)</p> </td>         <td align="center"> <p class="First">&nbsp;97 (3.6)</p> </td>         </tr>         <tr>          <td> <p class="First">Hematuria</p> </td>         <td align="center"> <p class="First">46 (1.7)</p> </td>         <td align="center"> <p class="First">102 (3.8)</p> </td>         </tr>         <tr>          <td> <p class="First">Menorrhagia</p> </td>         <td align="center"> <p class="First">38 (1.4)</p> </td>         <td align="center"> <p class="First">&nbsp;30 (1.1)</p> </td>         </tr>         <tr>          <td> <p class="First">Hematoma</p> </td>         <td align="center"> <p class="First">35 (1.3)</p> </td>         <td align="center"> <p class="First">&nbsp;76 (2.8)</p> </td>         </tr>         <tr>          <td> <p class="First">Hemoptysis</p> </td>         <td align="center"> <p class="First">32 (1.2)</p> </td>         <td align="center"> <p class="First">&nbsp;31 (1.2)</p> </td>         </tr>         <tr>          <td> <p class="First">Rectal hemorrhage</p> </td>         <td align="center"> <p class="First">26 (1.0)</p> </td>         <td align="center"> <p class="First">&nbsp;39 (1.5)</p> </td>         </tr>         <tr class="Last">          <td class="Botrule"> <p class="First">Gingival bleeding</p> </td>         <td class="Botrule" align="center"> <p class="First">26 (1.0)</p> </td>         <td class="Botrule" align="center"> <p class="First">&nbsp;50 (1.9)</p> </td>         </tr>        </tbody>       </table>     </div>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_0e695f73-6870-4a38-bba8-be344d6bc241"></a>     <a name="section-6.1.3.2"></a>      <p></p>      <h4>AMPLIFY-EXT Study</h4>      <p class="First">The mean duration of exposure to ELIQUIS was approximately 330 days and to placebo was 312 days in the AMPLIFY-EXT study. Adverse reactions related to bleeding occurred in 219 (13.3%) ELIQUIS-treated patients compared to 72 (8.7%) placebo-treated patients. The discontinuation rate due to bleeding events was approximately 1% in the ELIQUIS-treated patients compared to 0.4% in those patients in the placebo group in the AMPLIFY-EXT study.</p>      <p>Bleeding results from the AMPLIFY-EXT study are summarized in Table 7.</p>      <div class="scrollingtable">      <table>        <caption>         <span>Table 7:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bleeding Results in the AMPLIFY-EXT Study</span>        </caption>        <colgroup>        <col width="23%" />         <col width="23%" />         <col width="29%" />         <col width="40%" />        </colgroup>       <thead>         <tr class="First Last">          <th class="Botrule" valign="top"></th>         <th class="Botrule" valign="top">ELIQUIS 2.5 mg <br />N=840<br />n (%)</th>         <th class="Botrule" valign="top">ELIQUIS 5 mg <br />N=811<br />n (%)</th>         <th class="Botrule" valign="top">Placebo <br />N=826<br />n (%)</th>         </tr>        </thead>        <tfoot>         <tr class="First Last">          <td class="Botrule" align="left" colspan="4" valign="top">*&nbsp;&nbsp;&nbsp;CRNM = clinically relevant nonmajor bleeding.<br />Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.</td>         </tr>        </tfoot>        <tbody>         <tr class="First">          <td class="Toprule"> <p class="First">Major</p> </td>         <td class="Toprule" align="center"> <p class="First">2 (0.2)</p> </td>         <td class="Toprule" align="center"> <p class="First">1 (0.1)</p> </td>         <td class="Toprule" align="center"> <p class="First">4 (0.5)</p> </td>         </tr>         <tr>          <td> <p class="First">CRNM*</p> </td>         <td align="center"> <p class="First">25 (3.0)</p> </td>         <td align="center"> <p class="First">34 (4.2)</p> </td>         <td align="center"> <p class="First">19 (2.3)</p> </td>         </tr>         <tr>          <td> <p class="First">Major + CRNM</p> </td>         <td align="center"> <p class="First">27 (3.2)</p> </td>         <td align="center"> <p class="First">35 (4.3)</p> </td>         <td align="center"> <p class="First">22 (2.7)</p> </td>         </tr>         <tr>          <td> <p class="First">Minor</p> </td>         <td align="center"> <p class="First">75 (8.9)</p> </td>         <td align="center"> <p class="First">98 (12.1)</p> </td>         <td align="center"> <p class="First">58 (7.0)</p> </td>         </tr>         <tr class="Last">          <td class="Botrule"> <p class="First">All</p> </td>         <td class="Botrule" align="center"> <p class="First">94 (11.2)</p> </td>         <td class="Botrule" align="center"> <p class="First">121 (14.9)</p> </td>         <td class="Botrule" align="center"> <p class="First">74 (9.0)</p> </td>         </tr>        </tbody>       </table>     </div>      <p>Adverse reactions occurring in ≥1% of patients in the AMPLIFY-EXT study are listed in Table&nbsp;8.</p>      <div class="scrollingtable">      <table>        <caption>         <span>Table 8:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adverse Reactions Occurring in ≥1% of Patients Undergoing Extended Treatment for DVT and PE in the AMPLIFY-EXT Study</span>        </caption>        <colgroup>        <col width="29%" />         <col width="29%" />         <col width="29%" />         <col width="29%" />        </colgroup>       <thead>         <tr class="First Last">          <th class="Botrule Toprule" valign="top"></th>         <th class="Botrule Toprule" valign="top">ELIQUIS 2.5 mg<br />N=840 <br />n (%)</th>         <th class="Botrule Toprule" valign="top">ELIQUIS 5 mg<br />N=811<br />n (%)</th>         <th class="Botrule Toprule" valign="top">Placebo <br />N=826 <br />n (%)</th>         </tr>        </thead>        <tbody>         <tr class="First">          <td class="Toprule"> <p class="First">Epistaxis</p> </td>         <td class="Toprule" align="center"> <p class="First">13 (1.5)</p> </td>         <td class="Toprule" align="center"> <p class="First">29 (3.6)</p> </td>         <td class="Toprule" align="center"> <p class="First">9 (1.1)</p> </td>         </tr>         <tr>          <td> <p class="First">Hematuria</p> </td>         <td align="center"> <p class="First">12 (1.4)</p> </td>         <td align="center"> <p class="First">17 (2.1)</p> </td>         <td align="center"> <p class="First">9 (1.1)</p> </td>         </tr>         <tr>          <td> <p class="First">Hematoma</p> </td>         <td align="center"> <p class="First">13 (1.5)</p> </td>         <td align="center"> <p class="First">16 (2.0)</p> </td>         <td align="center"> <p class="First">10 (1.2)</p> </td>         </tr>         <tr>          <td> <p class="First">Contusion</p> </td>         <td align="center"> <p class="First">18 (2.1)</p> </td>         <td align="center"> <p class="First">18 (2.2)</p> </td>         <td align="center"> <p class="First">18 (2.2)</p> </td>         </tr>         <tr class="Last">          <td class="Botrule"> <p class="First">Gingival bleeding</p> </td>         <td class="Botrule" align="center"> <p class="RruleFirst">12 (1.4)</p> </td>         <td class="Botrule" align="center"> <p class="First">9 (1.1)</p> </td>         <td class="Botrule" align="center"> <p class="First">3 (0.4)</p> </td>         </tr>        </tbody>       </table>     </div>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_9236cf90-c496-4b29-97ab-134ee555f2a2"></a>     <a name="section-6.1.3.3"></a>      <p></p>      <h4>Other Adverse Reactions</h4>      <p class="First">Less common adverse reactions in ELIQUIS-treated patients in the AMPLIFY or AMPLIFY-EXT studies occurring at a frequency of ≥0.1% to &lt;1%:</p>      <p> <span class="Italics">Blood and lymphatic system disorders:</span> hemorrhagic anemia</p>      <p> <span class="Italics">Gastrointestinal disorders:</span> hematochezia, hemorrhoidal hemorrhage, gastrointestinal hemorrhage, hematemesis, melena, anal hemorrhage</p>      <p> <span class="Italics">Injury, poisoning, and procedural complications:</span> wound hemorrhage, postprocedural hemorrhage, traumatic hematoma, periorbital hematoma</p>      <p> <span class="Italics">Musculoskeletal and connective tissue disorders:</span> muscle hemorrhage</p>      <p> <span class="Italics">Reproductive system and breast disorders:</span> vaginal hemorrhage, metrorrhagia, menometrorrhagia, genital hemorrhage</p>      <p> <span class="Italics">Vascular disorders</span>: hemorrhage</p>      <p> <span class="Italics">Skin and subcutaneous tissue disorders:</span> ecchymosis, skin hemorrhage, petechiae</p>      <p> <span class="Italics">Eye disorders:</span> conjunctival hemorrhage, retinal hemorrhage, eye hemorrhage</p>      <p> <span class="Italics">Investigations:</span> blood urine present, occult blood positive, occult blood, red blood cells urine positive</p>      <p> <span class="Italics">General disorders and administration-site conditions:</span> injection-site hematoma, vessel puncture-site hematoma</p>     </div>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">7 DRUG INTERACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34073-7">   <a name="s7"></a>  <a name="section-7"></a>   <p></p>    <p class="First">Apixaban is a substrate of both CYP3A4 and P-gp. Inhibitors of CYP3A4 and P-gp increase exposure to apixaban and increase the risk of bleeding. Inducers of CYP3A4 and P-gp decrease exposure to apixaban and increase the risk of stroke and other thromboembolic events.</p>   <div class="Section" data-sectioncode="34073-7">    <a name="ID_9dd32361-75eb-49c7-a5c9-f6ec6c14aef9"></a>   <a name="section-7.1"></a>    <p></p>    <h2>7.1 Strong Dual Inhibitors of CYP3A4 and P-gp</h2>    <p class="First">For patients receiving ELIQUIS doses greater than 2.5 mg twice daily, the dose of ELIQUIS should be decreased by 50% when it is coadministered with drugs that are strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin) <span class="Italics">[see <a href="#s2.2">Dosage and Administration (2.2)</a> and <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>.</p>    <p>For patients receiving ELIQUIS at a dose of 2.5 mg twice daily, avoid coadministration with strong dual inhibitors of CYP3A4 and P-gp <span class="Italics">[see <a href="#s2.2">Dosage and Administration (2.2)</a> and <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="34073-7">    <a name="ID_8e0aba69-393f-478b-b422-a499729c12a2"></a>   <a name="section-7.2"></a>    <p></p>    <h2>7.2 Strong Dual Inducers of CYP3A4 and P-gp</h2>    <p class="First">Avoid concomitant use of ELIQUIS with strong dual inducers of CYP3A4 and P-gp (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban <span class="Italics">[see <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="34073-7">    <a name="ID_db976135-f7e4-4774-b901-842930552cf7"></a>   <a name="section-7.3"></a>    <p></p>    <h2>7.3 Anticoagulants and Antiplatelet Agents</h2>    <p class="First">Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding.</p>    <p>APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk, post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo. The rate of ISTH major bleeding was 2.77% per year with apixaban versus 0.62% per year with placebo in patients receiving single antiplatelet therapy and was 5.91% per year with apixaban versus 2.50% per year with placebo in those receiving dual antiplatelet therapy.</p>    <p>In ARISTOTLE, concomitant use of aspirin increased the bleeding risk on ELIQUIS from 1.8% per year to 3.4% per year and the bleeding risk on warfarin from 2.7% per year to 4.6% per year. In this clinical trial, there was limited (2.3%) use of dual antiplatelet therapy with ELIQUIS.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">8 USE IN SPECIFIC POPULATIONS</a> <div class="Section toggle-content closed" data-sectioncode="43684-0">   <a name="s8"></a>  <a name="section-8"></a>   <p></p>    <div class="Section" data-sectioncode="42228-7">    <a name="ID_47163af8-a468-4113-acd7-e6f01f361d71"></a>   <a name="section-8.1"></a>    <p></p>    <h2>8.1 Pregnancy</h2>    <div class="Section" data-sectioncode="34077-8">     <a name="ID_bed144a3-c52e-44d0-8037-bf749f8cb2ee"></a>    <a name="section-8.1.1"></a>     <p></p>     <h3>Pregnancy Category B</h3>     <p class="First">There are no adequate and well-controlled studies of ELIQUIS in pregnant women. Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery. ELIQUIS should be used during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus.</p>     <p>Treatment of pregnant rats, rabbits, and mice after implantation until the end of gestation resulted in fetal exposure to apixaban, but was not associated with increased risk for fetal malformations or toxicity. No maternal or fetal deaths were attributed to bleeding. Increased incidence of maternal bleeding was observed in mice, rats, and rabbits at maternal exposures that were 19, 4, and 1 times, respectively, the human exposure of unbound drug, based on area under plasma-concentration time curve (AUC) comparisons at the maximum recommended human dose (MRHD) of 10 mg (5 mg twice daily).</p>    </div>   </div>   <div class="Section" data-sectioncode="34079-4">    <a name="ID_7428b6f8-df88-4d43-a02c-df6f5952471e"></a>   <a name="section-8.2"></a>    <p></p>    <h2>8.2 Labor and Delivery</h2>    <p class="First">Safety and effectiveness of ELIQUIS during labor and delivery have not been studied in clinical trials. Consider the risks of bleeding and of stroke in using ELIQUIS in this setting <span class="Italics">[see <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">Warnings and Precautions (5.2)</a>]</span>.</p>    <p>Treatment of pregnant rats from implantation (gestation Day 7) to weaning (lactation Day 21) with apixaban at a dose of 1000 mg/kg (about 5 times the human exposure based on unbound apixaban) did not result in death of offspring or death of mother rats during labor in association with uterine bleeding. However, increased incidence of maternal bleeding, primarily during gestation, occurred at apixaban doses of ≥25 mg/kg, a dose corresponding to ≥1.3 times the human exposure.</p>   </div>   <div class="Section" data-sectioncode="34080-2">    <a name="ID_49c34a2e-e9f2-40b3-94d0-9c14d350890b"></a>   <a name="section-8.3"></a>    <p></p>    <h2>8.3 Nursing Mothers</h2>    <p class="First">It is unknown whether apixaban or its metabolites are excreted in human milk. Rats excrete apixaban in milk (12% of the maternal dose).</p>    <p>Women should be instructed either to discontinue breastfeeding or to discontinue ELIQUIS therapy, taking into account the importance of the drug to the mother.</p>   </div>   <div class="Section" data-sectioncode="34081-0">    <a name="ID_bf3844a3-6a1d-4ec6-8223-6a94850812bd"></a>   <a name="section-8.4"></a>    <p></p>    <h2>8.4 Pediatric Use</h2>    <p class="First">Safety and effectiveness in pediatric patients have not been established.</p>   </div>   <div class="Section" data-sectioncode="34082-8">    <a name="ID_241a3258-7bb0-43c0-b080-944566bf98df"></a>   <a name="section-8.5"></a>    <p></p>    <h2>8.5 Geriatric Use</h2>    <p class="First">Of the total subjects in the ARISTOTLE and AVERROES clinical studies, &gt;69% were 65 and older, and &gt;31% were 75 and older. In the ADVANCE-1, ADVANCE-2, and ADVANCE-3 clinical studies, 50% of subjects were 65 and older, while 16% were 75 and older. In the AMPLIFY and AMPLIFY-EXT clinical studies, &gt;32% of subjects were 65 and older and &gt;13% were 75 and older. No clinically significant differences in safety or effectiveness were observed when comparing subjects in different age groups.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_08b58613-14d0-431e-bbd5-fc25b4e4026f"></a>   <a name="section-8.6"></a>    <p></p>    <h2>8.6 End-Stage Renal Disease Patients Maintained with Hemodialysis</h2>    <p class="First">Patients with ESRD with or without hemodialysis were not studied in clinical efficacy and safety studies with ELIQUIS; therefore, the dosing recommendation for patients with nonvalvular atrial fibrillation is based on pharmacokinetic and pharmacodynamic (anti-Factor Xa activity) data in subjects with ESRD maintained on dialysis. The recommended dose for ESRD patients maintained with hemodialysis is 5 mg orally twice daily. For ESRD patients maintained with hemodialysis with one of the following patient characteristics, age ≥80 years or body weight ≤60 kg, reduce dose to 2.5 mg twice daily <span class="Italics">[see <a href="#s2.7">Dosage and Administration (2.7)</a> and <a href="#ID_ffcee25e-6f0f-469c-84d4-4258bdd2d986">Clinical Pharmacology (12.2</a>, <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">12.3)</a>]</span>.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">10 OVERDOSAGE</a> <div class="Section toggle-content closed" data-sectioncode="34088-5">   <a name="s10"></a>  <a name="section-9"></a>   <p></p>    <p class="First">There is no antidote to ELIQUIS. Overdose of ELIQUIS increases the risk of bleeding <span class="Italics">[see <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">Warnings and Precautions (5.2)</a>]</span>.</p>   <p>In controlled clinical trials, orally administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice daily for 7 days or 50 mg once daily for 3 days) had no clinically relevant adverse effects.</p>   <p>In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20-mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively. Thus, administration of activated charcoal may be useful in the management of apixaban overdose or accidental ingestion.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">11 DESCRIPTION</a> <div class="Section toggle-content closed" data-sectioncode="34089-3">   <a name="s11"></a>  <a name="section-10"></a>   <p></p>    <p class="First">ELIQUIS (apixaban), a factor Xa (FXa) inhibitor, is chemically described as 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1<span class="Italics">H</span>-pyrazolo[3,4-<span class="Italics">c</span>]pyridine-3-carboxamide. Its molecular formula is C<span class="Sub">25</span>H<span class="Sub">25</span>N<span class="Sub">5</span>O<span class="Sub">4</span>, which corresponds to a molecular weight of 459.5. Apixaban has the following structural formula:</p>   <div class="Figure">    <a name="id15675537"></a>   <img src="image.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0&name=apixaban%2Dstruct%2Ejpg" alt="Apixaban Chemical Structure" />  </div>   <p>Apixaban is a white to pale-yellow powder. At physiological pH (1.2–6.8), apixaban does not ionize; its aqueous solubility across the physiological pH range is ~0.04 mg/mL.</p>   <p>ELIQUIS tablets are available for oral administration in strengths of 2.5 mg and 5 mg of apixaban with the following inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetin, and yellow iron oxide (2.5 mg tablets) or red iron oxide (5 mg tablets).</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">12 CLINICAL PHARMACOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34090-1">   <a name="s12"></a>  <a name="section-11"></a>   <p></p>    <div class="Section" data-sectioncode="43679-0">    <a name="ID_0dba7108-252d-45bc-a285-d1a47eb77b40"></a>   <a name="section-11.1"></a>    <p></p>    <h2>12.1 Mechanism of Action</h2>    <p class="First">Apixaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.</p>   </div>   <div class="Section" data-sectioncode="43681-6">    <a name="ID_ffcee25e-6f0f-469c-84d4-4258bdd2d986"></a>   <a name="section-11.2"></a>    <p></p>    <h2>12.2 Pharmacodynamics</h2>    <p class="First">As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose, however, are small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of apixaban.</p>    <p>The Rotachrom<span class="Sup">&reg;</span> Heparin chromogenic assay was used to measure the effect of apixaban on FXa activity in humans during the apixaban development program. A concentration-dependent increase in anti-FXa activity was observed in the dose range tested and was similar in healthy subjects and patients with AF.</p>    <p>This test is not recommended for assessing the anticoagulant effect of apixaban.</p>    <div class="Section" data-sectioncode="43681-6">     <a name="ID_8c166241-72a8-4ee0-98e6-2ccb79faca6c"></a>    <a name="section-11.2.1"></a>     <p></p>     <h3>Pharmacodynamic Drug Interaction Studies</h3>     <p class="First">Pharmacodynamic drug interaction studies with aspirin, clopidogrel, aspirin and clopidogrel, prasugrel, enoxaparin, and naproxen were conducted. No pharmacodynamic interactions were observed with aspirin, clopidogrel, or prasugrel <span class="Italics">[see <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">Warnings and Precautions (5.2)</a>]</span>. A 50% to 60% increase in anti-FXa activity was observed when apixaban was coadministered with enoxaparin or naproxen.</p>    </div>    <div class="Section" data-sectioncode="43681-6">     <a name="ID_3d52486b-82e3-41c3-b9e2-65e3991507fc"></a>    <a name="section-11.2.2"></a>     <p></p>     <h3>Specific Populations</h3>     <p class="First"> <span class="Italics">Renal impairment:</span> Anti-FXa activity adjusted for exposure to apixaban was similar across renal function categories.</p>     <p> <span class="Italics">Hepatic impairment:</span> Changes in anti-FXa activity were similar in patients with mild-to-moderate hepatic impairment and healthy subjects. However, in patients with moderate hepatic impairment, there is no clear understanding of the impact of this degree of hepatic function impairment on the coagulation cascade and its relationship to efficacy and bleeding. Patients with severe hepatic impairment were not studied.</p>    </div>    <div class="Section" data-sectioncode="43681-6">     <a name="ID_e8488ae6-28be-4be8-a489-56a361918589"></a>    <a name="section-11.2.3"></a>     <p></p>     <h3>Cardiac Electrophysiology</h3>     <p class="First">Apixaban has no effect on the QTc interval in humans at doses up to 50 mg.</p>    </div>   </div>   <div class="Section" data-sectioncode="43682-4">    <a name="ID_0138578a-a58b-4cad-b354-271d6b1854d1"></a>   <a name="section-11.3"></a>    <p></p>    <h2>12.3 Pharmacokinetics</h2>    <p class="First">Apixaban demonstrates linear pharmacokinetics with dose-proportional increases in exposure for oral doses up to 10 mg.</p>    <div class="Section" data-sectioncode="43682-4">     <a name="ID_ec69f4ee-86ee-4e9e-862a-36791e769688"></a>    <a name="section-11.3.1"></a>     <p></p>     <h3>Absorption</h3>     <p class="First">The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of ELIQUIS. Food does not affect the bioavailability of apixaban. Maximum concentrations (C<span class="Sub">max</span>) of apixaban appear 3 to 4 hours after oral administration of ELIQUIS. At doses ≥25 mg, apixaban displays dissolution-limited absorption with decreased bioavailability. Following administration of a crushed 5 mg ELIQUIS tablet that was suspended in 60 mL D5W and delivered through a nasogastric tube (NGT), exposure was similar to that seen in other clinical trials involving healthy volunteers receiving a single oral 5 mg tablet dose.</p>    </div>    <div class="Section" data-sectioncode="43682-4">     <a name="ID_eac74eab-a357-493f-aecd-ae962268230f"></a>    <a name="section-11.3.2"></a>     <p></p>     <h3>Distribution</h3>     <p class="First">Plasma protein binding in humans is approximately 87%. The volume of distribution (Vss) is approximately 21 liters.</p>    </div>    <div class="Section" data-sectioncode="43682-4">     <a name="ID_f1071a5b-3a44-480d-ade8-14f548cb1d88"></a>    <a name="section-11.3.3"></a>     <p></p>     <h3>Metabolism</h3>     <p class="First">Approximately 25% of an orally administered apixaban dose is recovered in urine and feces as metabolites. Apixaban is metabolized mainly via CYP3A4 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2. O-demethylation and hydroxylation at the 3-oxopiperidinyl moiety are the major sites of biotransformation.</p>     <p>Unchanged apixaban is the major drug-related component in human plasma; there are no active circulating metabolites.</p>    </div>    <div class="Section" data-sectioncode="43682-4">     <a name="ID_e8e775ce-ad39-4a0a-9d25-45ddd1d2153d"></a>    <a name="section-11.3.4"></a>     <p></p>     <h3>Elimination</h3>     <p class="First">Apixaban is eliminated in both urine and feces. Renal excretion accounts for about 27% of total clearance. Biliary and direct intestinal excretion contributes to elimination of apixaban in the feces.</p>     <p>Apixaban has a total clearance of approximately 3.3 L/hour and an apparent half-life of approximately 12 hours following oral administration.</p>     <p>Apixaban is a substrate of transport proteins: P-gp and breast cancer resistance protein.</p>    </div>    <div class="Section" data-sectioncode="43682-4">     <a name="ID_c4cbfa56-4b06-4991-acc2-88b1ee619240"></a>    <a name="section-11.3.5"></a>     <p></p>     <h3>Drug Interaction Studies</h3>     <p class="First"> <span class="Italics">In vitro</span> apixaban studies at concentrations significantly greater than therapeutic exposures, no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP3A4/5, or CYP2C19, nor induction effect on the activity of CYP1A2, CYP2B6, or CYP3A4/5 were observed. Therefore, apixaban is not expected to alter the metabolic clearance of coadministered drugs that are metabolized by these enzymes. Apixaban is not a significant inhibitor of P-gp.</p>     <p>The effects of coadministered drugs on the pharmacokinetics of apixaban and associated dose recommendations are summarized in Figure 2 <span class="Italics">[see also <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">Warnings and Precautions (5.2)</a> and <a href="#s7">Drug Interactions (7)</a>]</span>.</p>     <p>Figure <a href="#">2</a>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of Coadministered Drugs on the Pharmacokinetics of Apixaban</p>     <div class="Figure">      <a name="id6195948"></a>     <img src="image.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0&name=eliquis%2Dpkplot%2Ddrugs%2Dfig2%2Ejpg" alt="Effect of drugs on PK" />    </div>     <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;Dashed vertical lines illustrate pharmacokinetic changes that were used to inform<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dosing recommendations. Dosing recommendations were also informed by<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;clinical considerations <span class="Italics">[see <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">Warnings and Precautions (5.2)</a> and <a href="#s7">Drug Interactions (7)</a>]</span>.</p>     <p>In dedicated studies conducted in healthy subjects, famotidine, atenolol, prasugrel, and enoxaparin did not meaningfully alter the pharmacokinetics of apixaban.</p>     <p>In studies conducted in healthy subjects, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, atenolol, prasugrel, or acetylsalicylic acid.</p>    </div>    <div class="Section" data-sectioncode="43682-4">     <a name="ID_31f13068-b6ac-44d1-8d24-eb05503bcdce"></a>    <a name="section-11.3.6"></a>     <p></p>     <h3>Specific Populations</h3>     <p class="First">The effects of level of renal impairment, age, body weight, and level of hepatic impairment on the pharmacokinetics of apixaban are summarized in Figure 3.</p>     <p>Figure <a href="#">3</a>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of Specific Populations on the Pharmacokinetics of Apixaban</p>     <div class="Figure">      <a name="id15674025"></a>     <img src="image.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0&name=eliquis%2Dpkplot%2Dpop%2Dfig3%2Ejpg" alt="Effect of Populations on PK" />    </div>     <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;ESRD subjects maintained with chronic and stable hemodialysis; reported PK findings <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;are following single dose of apixaban post hemodialysis.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span class="Sup">†</span>&nbsp;&nbsp;Creatinine clearance 15 to 29 mL/min.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span class="Sup">‡</span>&nbsp;&nbsp;Dashed vertical lines illustrate pharmacokinetic changes that were used to inform <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dosing recommendations.</p>     <p>A study in healthy subjects comparing the pharmacokinetics in males and females showed no meaningful difference.</p>     <p>The results across pharmacokinetic studies in normal subjects showed no differences in apixaban pharmacokinetics among White/Caucasian, Asian, and Black/African American subjects. No dose adjustment is required based on race/ethnicity.</p>     <p>In subjects with ESRD, a 4-hour hemodialysis session with a dialysate flow rate of 500 mL/min and a blood flow rate in the range of 350 to 500 mL/min started 2 hours after administration of a single 5 mg dose of apixaban, the AUC of apixaban was 17% greater compared to those with normal renal function. The dialysis clearance of apixaban is approximately 18 mL/min resulting in a 14% decrease in exposure due to hemodialysis compared to off-dialysis period.</p>     <p>Protein binding was similar (92%-94%) between healthy controls and the on-dialysis and off-dialysis periods.</p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">13 NONCLINICAL TOXICOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="43680-8">   <a name="s13"></a>  <a name="section-12"></a>   <p></p>    <div class="Section" data-sectioncode="34083-6">    <a name="ID_63b61b63-cdb1-49f3-bf28-6bbac58b34c5"></a>   <a name="section-12.1"></a>    <p></p>    <h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>    <p class="First"> <span class="Italics">Carcinogenesis:</span> Apixaban was not carcinogenic when administered to mice and rats for up to 2 years. The systemic exposures (AUCs) of unbound apixaban in male and female mice at the highest doses tested (1500 and 3000 mg/kg/day) were 9 and 20 times, respectively, the human exposure of unbound drug at the MRHD of 10 mg/day. Systemic exposures of unbound apixaban in male and female rats at the highest dose tested (600 mg/kg/day) were 2 and 4 times, respectively, the human exposure.</p>    <p> <span class="Italics">Mutagenesis:</span> Apixaban was neither mutagenic in the bacterial reverse mutation (Ames) assay, nor clastogenic in Chinese hamster ovary cells <span class="Italics">in vitro</span>, in a 1-month <span class="Italics">in vivo/in vitro</span> cytogenetics study in rat peripheral blood lymphocytes, or in a rat micronucleus study <span class="Italics">in vivo</span>.</p>    <p> <span class="Italics">Impairment of Fertility:</span> Apixaban had no effect on fertility in male or female rats when given at doses up to 600 mg/kg/day, a dose resulting in exposure levels that are 3 and 4 times, respectively, the human exposure.</p>    <p>Apixaban administered to female rats at doses up to 1000 mg/kg/day from implantation through the end of lactation produced no adverse findings in male offspring (F<span class="Sub">1</span> generation) at doses up to 1000 mg/kg/day, a dose resulting in exposure that is 5 times the human exposure. Adverse effects in the F<span class="Sub">1</span>-generation female offspring were limited to decreased mating and fertility indices at 1000 mg/kg/day.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">14 CLINICAL STUDIES</a> <div class="Section toggle-content closed" data-sectioncode="34092-7">   <a name="s14"></a>  <a name="section-13"></a>   <p></p>    <div class="Section" data-sectioncode="34092-7">    <a name="ID_a7613d0d-0fcb-40e6-9339-beecd55c7497"></a>   <a name="section-13.1"></a>    <p></p>    <h2>14.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_f2b61ad8-875a-4be4-8703-e24e8ec80fee"></a>    <a name="section-13.1.1"></a>     <p></p>     <h3>ARISTOTLE</h3>     <p class="First">Evidence for the efficacy and safety of ELIQUIS was derived from ARISTOTLE, a multinational, double-blind study in patients with nonvalvular AF comparing the effects of ELIQUIS and warfarin on the risk of stroke and non-central nervous system (CNS) systemic embolism. In ARISTOTLE, patients were randomized to ELIQUIS 5 mg orally twice daily (or 2.5 mg twice daily in subjects with at least 2 of the following characteristics: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL) or to warfarin (targeted to an INR range of 2.0–3.0). Patients had to have one or more of the following additional risk factors for stroke:</p>     <dl>      <dt>      ●     </dt>      <dd>      prior stroke or transient ischemic attack (TIA)     </dd>      <dt>      ●     </dt>      <dd>      prior systemic embolism     </dd>      <dt>      ●     </dt>      <dd>      age ≥75 years     </dd>      <dt>      ●     </dt>      <dd>      arterial hypertension requiring treatment     </dd>      <dt>      ●     </dt>      <dd>      diabetes mellitus     </dd>      <dt>      ●     </dt>      <dd>      heart failure ≥New York Heart Association Class 2     </dd>      <dt>      ●     </dt>      <dd>      left ventricular ejection fraction ≤40%     </dd>     </dl>     <p>The primary objective of ARISTOTLE was to determine whether ELIQUIS 5 mg twice daily (or 2.5 mg twice daily) was effective (noninferior to warfarin) in reducing the risk of stroke (ischemic or hemorrhagic) and systemic embolism. Superiority of ELIQUIS to warfarin was also examined for the primary endpoint (rate of stroke and systemic embolism), major bleeding, and death from any cause.</p>     <p>A total of 18,201 patients were randomized and followed on study treatment for a median of 89 weeks. Forty-three percent of patients were vitamin K antagonist (VKA) “naive,” defined as having received ≤30 consecutive days of treatment with warfarin or another VKA before entering the study. The mean age was 69 years and the mean CHADS<span class="Sub">2</span> score (a scale from 0 to 6 used to estimate risk of stroke, with higher scores predicting greater risk) was 2.1. The population was 65% male, 83% Caucasian, 14% Asian, and 1% Black. There was a history of stroke, TIA, or non-CNS systemic embolism in 19% of patients. Concomitant diseases of patients in this study included hypertension 88%, diabetes 25%, congestive heart failure (or left ventricular ejection fraction ≤40%) 35%, and prior myocardial infarction 14%. Patients treated with warfarin in ARISTOTLE had a mean percentage of time in therapeutic range (INR 2.0–3.0) of 62%.</p>     <p>ELIQUIS was superior to warfarin for the primary endpoint of reducing the risk of stroke and systemic embolism (Table 9 and Figure 4). Superiority to warfarin was primarily attributable to a reduction in hemorrhagic stroke and ischemic strokes with hemorrhagic conversion compared to warfarin. Purely ischemic strokes occurred with similar rates on both drugs.</p>     <p>ELIQUIS also showed significantly fewer major bleeds than warfarin <span class="Italics">[see <a href="#ID_e2e3f133-ee9c-4781-bcd7-3af1586e9ead">Adverse Reactions (6.1)</a>]</span>.</p>     <div class="scrollingtable">     <table>       <caption>        <span>Table 9:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Key Efficacy Outcomes in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE (Intent-to-Treat Analysis)</span>       </caption>       <colgroup>       <col width="49%" />        <col width="16%" />        <col width="16%" />        <col width="18%" />        <col width="15%" />       </colgroup>      <thead>        <tr class="First Last">         <th class="Botrule Toprule" valign="top"></th>        <th class="Botrule Toprule" valign="top">ELIQUIS<br />N=9120<br />n (%/year)</th>        <th class="Botrule Toprule" valign="top">Warfarin<br />N=9081<br />n (%/year)</th>        <th class="Botrule Toprule" valign="top">Hazard Ratio<br />(95% CI)</th>        <th class="Botrule Toprule" valign="top">P-value</th>        </tr>       </thead>       <tfoot>        <tr class="First Last">         <td class="Botrule" align="left" colspan="5" valign="top">The primary endpoint was based on the time to first event (one per subject). Component counts are for subjects with any event, not necessarily the first.</td>        </tr>       </tfoot>       <tbody>        <tr class="First">         <td class="Toprule"> <p class="First">Stroke or systemic embolism</p> </td>        <td class="Toprule" align="center"> <p class="First">212 (1.27)</p> </td>        <td class="Toprule" align="center"> <p class="First">265 (1.60)</p> </td>        <td class="Toprule" align="center"> <p class="First">0.79 (0.66, 0.95)</p> </td>        <td class="Toprule" align="center"> <p class="First">0.01</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;&nbsp;Stroke</p> </td>        <td align="center"> <p class="First">199 (1.19)</p> </td>        <td align="center"> <p class="First">250 (1.51)</p> </td>        <td align="center"> <p class="First">0.79 (0.65, 0.95)</p> </td>        <td></td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ischemic without hemorrhage</p> </td>        <td align="center"> <p class="First">140 (0.83)</p> </td>        <td align="center"> <p class="First">136 (0.82)</p> </td>        <td align="center"> <p class="First">1.02 (0.81, 1.29)</p> </td>        <td></td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ischemic with hemorrhagic conversion</p> </td>        <td align="center"> <p class="First">12 (0.07)</p> </td>        <td align="center"> <p class="First">20 (0.12)</p> </td>        <td align="center"> <p class="First">0.60 (0.29, 1.23)</p> </td>        <td></td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hemorrhagic</p> </td>        <td align="center"> <p class="First">40 (0.24)</p> </td>        <td align="center"> <p class="First">78 (0.47)</p> </td>        <td align="center"> <p class="First">0.51 (0.35, 0.75)</p> </td>        <td></td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unknown</p> </td>        <td align="center"> <p class="First">14 (0.08)</p> </td>        <td align="center"> <p class="First">21 (0.13)</p> </td>        <td align="center"> <p class="First">0.65 (0.33, 1.29)</p> </td>        <td></td>        </tr>        <tr class="Last">         <td class="Botrule"> <p class="First">&nbsp;&nbsp;&nbsp;Systemic embolism</p> </td>        <td class="Botrule" align="center"> <p class="First">15 (0.09)</p> </td>        <td class="Botrule" align="center"> <p class="First">17 (0.10)</p> </td>        <td class="Botrule" align="center"> <p class="First">0.87 (0.44, 1.75)</p> </td>        <td class="Botrule"></td>        </tr>       </tbody>      </table>    </div>     <p>Figure <a href="#">4</a>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kaplan-Meier Estimate of Time to First Stroke or Systemic Embolism in ARISTOTLE (Intent-to-Treat Population)</p>     <div class="Figure">      <a name="id20059188"></a>     <img src="image.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0&name=eliquis%2Dkm%2Dfig4%2Ejpg" alt="ARISTOTLE Kaplan-Meier Curve" />    </div>     <p>All-cause death was assessed using a sequential testing strategy that allowed testing for superiority if effects on earlier endpoints (stroke plus systemic embolus and major bleeding) were demonstrated. ELIQUIS treatment resulted in a significantly lower rate of all-cause death (p = 0.046) than did treatment with warfarin, primarily because of a reduction in cardiovascular death, particularly stroke deaths. Non-vascular death rates were similar in the treatment arms.</p>     <p>In ARISTOTLE, the results for the primary efficacy endpoint were generally consistent across most major subgroups including weight, CHADS<span class="Sub">2</span> score (a scale from 0 to 6 used to predict risk of stroke in patients with AF, with higher scores predicting greater risk), prior warfarin use, level of renal impairment, geographic region, ELIQUIS dose, type of AF, and aspirin use at randomization (Figure 5).</p>     <p>Figure <a href="#">5</a>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stroke and Systemic Embolism Hazard Ratios by Baseline Characteristics – ARISTOTLE Study</p>     <div class="Figure">      <a name="id15692707"></a>     <img src="image.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0&name=eliquis%2Dclin%2Dforest%2Dfig5%2Ejpg" alt="ARISTOTLE Forest Plot " />    </div>     <p>At the end of the ARISTOTLE study, warfarin patients who completed the study were generally maintained on a VKA with no interruption of anticoagulation. ELIQUIS patients who completed the study were generally switched to a VKA with a 2-day period of coadministration of ELIQUIS and VKA, so that some patients may not have been adequately anticoagulated after stopping ELIQUIS until attaining a stable and therapeutic INR. During the 30 days following the end of the study, there were 21 stroke or systemic embolism events in the 6791 patients (0.3%) in the ELIQUIS arm compared to 5 in the 6569 patients (0.1%) in the warfarin arm <span class="Italics">[see <a href="#s2.5">Dosage and Administration (2.5)</a>]</span>.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_52748f50-0952-4e20-8d7b-12d454981109"></a>    <a name="section-13.1.2"></a>     <p></p>     <h3>AVERROES</h3>     <p class="First">In AVERROES, patients with nonvalvular atrial fibrillation thought not to be candidates for warfarin therapy were randomized to treatment with ELIQUIS 5 mg orally twice daily (or 2.5 mg twice daily in selected patients) or aspirin 81 to 324 mg once daily. The primary objective of the study was to determine if ELIQUIS was superior to aspirin for preventing the composite outcome of stroke or systemic embolism. AVERROES was stopped early on the basis of a prespecified interim analysis showing a significant reduction in stroke and systemic embolism for ELIQUIS compared to aspirin that was associated with a modest increase in major bleeding (Table 10) <span class="Italics">[see <a href="#ID_e2e3f133-ee9c-4781-bcd7-3af1586e9ead">Adverse Reactions (6.1)</a>]</span>.</p>     <div class="scrollingtable">     <table>       <caption>        <span>Table 10: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Key Efficacy Outcomes in Patients with Nonvalvular Atrial Fibrillation in AVERROES</span>       </caption>       <colgroup>       <col width="49%" />        <col width="16%" />        <col width="16%" />        <col width="18%" />        <col width="15%" />       </colgroup>      <thead>        <tr class="First Last">         <th class="Botrule Toprule" valign="top"></th>        <th class="Botrule Toprule" valign="top"><span class="Bold">ELIQUIS<br />N=2807<br />n (%/year)</span></th>        <th class="Botrule Toprule" valign="top"><span class="Bold">Aspirin<br />N=2791<br />n (%/year)</span></th>        <th class="Botrule Toprule" valign="top"><span class="Bold">Hazard Ratio<br />(95% CI)</span></th>        <th class="Botrule Toprule" valign="top"><span class="Bold">P-value</span></th>        </tr>       </thead>       <tbody>        <tr class="First">         <td class="Toprule"> <p class="First">Stroke or systemic embolism</p> </td>        <td class="Toprule" align="center"> <p class="First">51 (1.62)</p> </td>        <td class="Toprule" align="center"> <p class="First">113 (3.63)</p> </td>        <td class="Toprule" align="center"> <p class="First">0.45 (0.32, 0.62)</p> </td>        <td class="Toprule" align="center"> <p class="First">&lt;0.0001</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;&nbsp;Stroke</p> </td>        <td></td>        <td></td>        <td></td>        <td></td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ischemic or undetermined</p> </td>        <td align="center"> <p class="First">43 (1.37)</p> </td>        <td align="center"> <p class="First">97 (3.11)</p> </td>        <td align="center"> <p class="First">0.44 (0.31, 0.63)</p> </td>        <td align="center"> <p class="First">-</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hemorrhagic</p> </td>        <td align="center"> <p class="First">6 (0.19)</p> </td>        <td align="center"> <p class="First">9 (0.28)</p> </td>        <td align="center"> <p class="First">0.67 (0.24, 1.88)</p> </td>        <td align="center"> <p class="First">-</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;&nbsp;Systemic embolism</p> </td>        <td align="center"> <p class="First">2 (0.06)</p> </td>        <td align="center"> <p class="First">13 (0.41)</p> </td>        <td align="center"> <p class="First">0.15 (0.03, 0.68)</p> </td>        <td align="center"> <p class="First">-</p> </td>        </tr>        <tr>         <td> <p class="First">MI</p> </td>        <td align="center"> <p class="First">24 (0.76)</p> </td>        <td align="center"> <p class="First">28 (0.89)</p> </td>        <td align="center"> <p class="First">0.86 (0.50, 1.48)</p> </td>        <td align="center"> <p class="First">-</p> </td>        </tr>        <tr>         <td> <p class="First">All-cause death</p> </td>        <td align="center"> <p class="First">111 (3.51)</p> </td>        <td align="center"> <p class="First">140 (4.42)</p> </td>        <td align="center"> <p class="First">0.79 (0.62, 1.02)</p> </td>        <td align="center"> <p class="First">0.068</p> </td>        </tr>        <tr class="Last">         <td class="Botrule"> <p class="First">&nbsp;&nbsp;&nbsp;Vascular death</p> </td>        <td class="Botrule" align="center"> <p class="First">84 (2.65)</p> </td>        <td class="Botrule" align="center"> <p class="First">96 (3.03)</p> </td>        <td class="Botrule" align="center"> <p class="First">0.87 (0.65, 1.17)</p> </td>        <td class="Botrule" align="center"> <p class="First">-</p> </td>        </tr>       </tbody>      </table>    </div>    </div>   </div>   <div class="Section" data-sectioncode="34092-7">    <a name="ID_edafa3f2-e1fb-49b7-8625-a1625bb90464"></a>   <a name="section-13.2"></a>    <p></p>    <h2>14.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery</h2>    <p class="First">The clinical evidence for the effectiveness of ELIQUIS is derived from the ADVANCE-1, ADVANCE-2, and ADVANCE-3 clinical trials in adult patients undergoing elective hip (ADVANCE-3) or knee (ADVANCE-2 and ADVANCE-1) replacement surgery. A total of 11,659 patients were randomized in 3 double-blind, multi-national studies. Included in this total were 1866 patients age 75 or older, 1161 patients with low body weight (≤60 kg), 2528 patients with Body Mass Index ≥33&nbsp;kg/m<span class="Sup">2</span>, and 625 patients with severe or moderate renal impairment.</p>    <p>In the ADVANCE-3 study, 5407 patients undergoing elective hip replacement surgery were randomized to receive either ELIQUIS 2.5 mg orally twice daily or enoxaparin 40 mg subcutaneously once daily. The first dose of ELIQUIS was given 12 to 24 hours post surgery, whereas enoxaparin was started 9 to 15 hours prior to surgery. Treatment duration was 32 to 38 days.</p>    <p>In patients undergoing elective knee replacement surgery, ELIQUIS 2.5 mg orally twice daily was compared to enoxaparin 40 mg subcutaneously once daily (ADVANCE-2, N=3057) or enoxaparin 30 mg subcutaneously every 12 hours (ADVANCE-1, N=3195). In the ADVANCE-2 study, the first dose of ELIQUIS was given 12 to 24 hours post surgery, whereas enoxaparin was started 9 to 15 hours prior to surgery. In the ADVANCE-1 study, both ELIQUIS and enoxaparin were initiated 12 to 24 hours post surgery. Treatment duration in both ADVANCE-2 and ADVANCE-1 was 10 to 14 days.</p>    <p>In all 3 studies, the primary endpoint was a composite of adjudicated asymptomatic and symptomatic DVT, nonfatal PE, and all-cause death at the end of the double-blind intended treatment period. In ADVANCE-3 and ADVANCE-2, the primary endpoint was tested for noninferiority, then superiority, of ELIQUIS to enoxaparin. In ADVANCE-1, the primary endpoint was tested for noninferiority of ELIQUIS to enoxaparin.</p>    <p>The efficacy data are provided in Tables 11 and 12.</p>    <div class="scrollingtable">    <table>      <caption>       <span>Table 11: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Summary of Key Efficacy Analysis Results During the Intended Treatment Period for Patients Undergoing Elective Hip Replacement Surgery*</span>      </caption>      <colgroup>      <col width="48%" />       <col width="24%" />       <col width="21%" />       <col width="22%" />      </colgroup>     <tfoot>       <tr class="First Last">        <td class="Botrule" align="left" colspan="4" valign="top">*&nbsp;&nbsp;&nbsp;Events associated with each endpoint were counted once per subject but subjects may have contributed events to multiple endpoints.<br /> <span class="Sup">†</span>&nbsp;&nbsp;&nbsp;Total VTE includes symptomatic and asymptomatic DVT and PE.<br /> <span class="Sup">‡</span>&nbsp;&nbsp;&nbsp;Includes symptomatic and asymptomatic DVT.</td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Rrule Toprule"></td>       <td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"> <p class="First"> <span class="Bold">ADVANCE-3</span> </p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule"> <p class="First">Events During 35-Day Treatment Period</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">ELIQUIS<br />2.5 mg po bid</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">Enoxaparin <br />40 mg sc qd</p> </td>       <td class="Botrule Lrule Toprule" align="center"> <p class="First">Relative Risk<br />(95% CI)<br />P-value</p> </td>       </tr>       <tr>        <td class="Botrule Rrule"> <p class="First"> <span class="Bold">Number of Patients</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1949</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1917</span> </p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule"> <p class="First">Total VTE<span class="Sup">†</span>/All-cause death</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">27 (1.39%)<br />(0.95, 2.02)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">74 (3.86%)<br />(3.08, 4.83)</p> </td>       <td class="Botrule Lrule Toprule" align="center"> <p class="First">0.36<br />(0.22, 0.54)<br />p&lt;0.0001</p> </td>       </tr>       <tr>        <td class="Botrule Rrule"> <p class="First"> <span class="Bold">Number of Patients</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=2708</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=2699</span> </p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule"> <p class="First">&nbsp;&nbsp;All-cause death</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">3 (0.11%)<br />(0.02, 0.35)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">1 (0.04%)<br />(0.00, 0.24)</p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule"> <p class="First">&nbsp;&nbsp;PE</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">3 (0.11%)<br />(0.02, 0.35)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">5 (0.19%)<br />(0.07, 0.45)</p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule"> <p class="First">&nbsp;&nbsp;Symptomatic DVT</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">1 (0.04%)<br />(0.00, 0.24)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">5 (0.19%)<br />(0.07, 0.45)</p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule"> <p class="First"> <span class="Bold">Number of Patients</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=2196</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=2190</span> </p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule"> <p class="First">&nbsp;&nbsp;Proximal DVT<span class="Sup">‡</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">7 (0.32%)<br />(0.14, 0.68)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">20 (0.91%)<br />(0.59, 1.42)</p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule"> <p class="First"> <span class="Bold">Number of Patients</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1951</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1908</span> </p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr class="Last">        <td class="Botrule Rrule Toprule"> <p class="First">&nbsp;&nbsp;Distal DVT<span class="Sup">‡</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">20 (1.03%)<br />(0.66, 1.59)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">57 (2.99%)<br />(2.31, 3.86)</p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>      </tbody>     </table>   </div>    <div class="scrollingtable">    <table>      <caption>       <span>Table 12:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Summary of Key Efficacy Analysis Results During the Intended Treatment Period for Patients Undergoing Elective Knee Replacement Surgery*</span>      </caption>      <colgroup>      <col width="20%" />       <col width="17%" />       <col width="18%" />       <col width="14%" />       <col width="16%" />       <col width="16%" />       <col width="14%" />      </colgroup>     <thead>       <tr class="First Last">        <th class="Botrule Rrule Toprule" valign="top"></th>       <th class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><span class="Bold">ADVANCE-1</span></th>       <th class="Botrule Lrule Toprule" colspan="3" valign="top"><span class="Bold">ADVANCE-2</span></th>       </tr>      </thead>      <tfoot>       <tr class="First Last">        <td class="Botrule" align="left" colspan="11" valign="top">*&nbsp;&nbsp;&nbsp;Events associated with each endpoint were counted once per subject but subjects may have contributed events to multiple endpoints.<br /> <span class="Sup">†</span>&nbsp;&nbsp;&nbsp;Total VTE includes symptomatic and asymptomatic DVT and PE.<br /> <span class="Sup">‡</span>&nbsp;&nbsp;&nbsp;Includes symptomatic and asymptomatic DVT.</td>       </tr>      </tfoot>      <tbody>       <tr class="First">        <td class="Botrule Rrule Toprule"> <p class="First">Events during <br />12-day treatment period</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">ELIQUIS <br />2.5 mg po bid</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">Enoxaparin <br />30 mg sc q12h</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">Relative Risk<br /> (95% CI)<br />P-value</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">ELIQUIS <br />2.5 mg po bid</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">Enoxaparin <br />40 mg sc </p> <p>qd</p> </td>       <td class="Botrule Lrule Toprule" align="center"> <p class="First">Relative Risk<br />(95% CI)</p> <p>P-value</p> </td>       </tr>       <tr>        <td class="Botrule Rrule Toprule"> <p class="First"> <span class="Bold">Number of Patients</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1157</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1130</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule"></td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=976</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=997</span> </p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule Toprule"> <p class="First">Total VTE<span class="Sup">†</span>/All-cause death</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">104 (8.99%) <br />(7.47, 10.79)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">100 (8.85%) <br />(7.33, 10.66)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">1.02<br />(0.78, 1.32)<br />NS</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">147 (15.06%)<br />(12.95, 17.46)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">243 (24.37%) <br />(21.81, 27.14)</p> </td>       <td class="Botrule Lrule Toprule" align="center"> <p class="First">0.62<br />(0.51, 0.74)<br />p&lt;0.0001</p> </td>       </tr>       <tr>        <td class="Botrule Rrule Toprule"> <p class="First"> <span class="Bold">Number of Patients</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1599</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1596</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule"></td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1528</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1529</span> </p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule Toprule"> <p class="First">&nbsp;&nbsp;All-cause death</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">3 (0.19%)<br />(0.04, 0.59)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">3 (0.19%)<br />(0.04, 0.59)</p> </td>       <td class="Botrule Lrule Rrule Toprule"></td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">2 (0.13%)<br />(0.01, 0.52)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">0 (0%)<br />(0.00, 0.31)</p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule Toprule"> <p class="First">&nbsp;&nbsp;PE </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">16 (1.0%)<br />(0.61, 1.64)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">7 (0.44%)<br />(0.20, 0.93)</p> </td>       <td class="Botrule Lrule Rrule Toprule"></td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">4 (0.26%)<br />(0.08, 0.70)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">0 (0%)<br />(0.00, 0.31)</p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule Toprule"> <p class="First">&nbsp;&nbsp;Symptomatic<br />&nbsp;&nbsp;DVT</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">3 (0.19%)<br />(0.04, 0.59)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">7 (0.44%)<br />(0.20, 0.93)</p> </td>       <td class="Botrule Lrule Rrule Toprule"></td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">3 (0.20%)<br />(0.04, 0.61)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">7 (0.46%)<br />(0.20, 0.97)</p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule Toprule"> <p class="First"> <span class="Bold">Number of Patients</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1254</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1207</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule"></td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1192</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1199</span> </p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule Toprule"> <p class="First">&nbsp;&nbsp;Proximal DVT<span class="Sup">‡</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">9 (0.72%)<br />(0.36, 1.39)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">11 (0.91%)<br />(0.49, 1.65)</p> </td>       <td class="Botrule Lrule Rrule Toprule"></td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">9 (0.76%)<br />(0.38, 1.46)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">26 (2.17%)<br />(1.47, 3.18)</p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr>        <td class="Botrule Rrule Toprule"> <p class="First"> <span class="Bold">Number of Patients</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1146</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1133</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule"></td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=978</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"> <span class="Bold">N=1000</span> </p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>       <tr class="Last">        <td class="Botrule Rrule Toprule"> <p class="First">&nbsp;&nbsp;Distal DVT<span class="Sup">‡</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">83 (7.24%)<br />(5.88, 8.91)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">91 (8.03%)<br />(6.58, 9.78)</p> </td>       <td class="Botrule Lrule Rrule Toprule"></td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">142 (14.52%)<br />(12.45, 16.88)</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">239 (23.9%)<br />(21.36, 26.65)</p> </td>       <td class="Botrule Lrule Toprule"></td>       </tr>      </tbody>     </table>   </div>    <p>The efficacy profile of ELIQUIS was generally consistent across subgroups of interest for this indication (e.g., age, gender, race, body weight, renal impairment).</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_6fbc57af-782c-454d-9206-5ff789fe7c5b"></a>   <a name="section-13.3"></a>    <p></p>    <h2>14.3 Treatment of DVT and PE and Reduction in the Risk of Recurrence of DVT and PE</h2>    <p class="First">Efficacy and safety of ELIQUIS for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following 6 to 12 months of anticoagulant treatment was derived from the AMPLIFY and AMPLIFY-EXT studies. Both studies were randomized, parallel-group, double-blind trials in patients with symptomatic proximal DVT and/or symptomatic PE. All key safety and efficacy endpoints were adjudicated in a blinded manner by an independent committee.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_c0b5a3ec-53fe-4d44-abdb-e463d3c0abe1"></a>    <a name="section-13.3.1"></a>     <p></p>     <h3>AMPLIFY</h3>     <p class="First">The primary objective of AMPLIFY was to determine whether ELIQUIS was noninferior to enoxaparin/warfarin for the incidence of recurrent VTE (venous thromboembolism) or VTE-related death. Patients with an objectively confirmed symptomatic DVT and/or PE were randomized to treatment with ELIQUIS 10 mg twice daily orally for 7 days followed by ELIQUIS 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR ≥2) followed by warfarin (target INR range 2.0-3.0) orally for 6 months. Patients who required thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent, and patients with creatinine clearance &lt;25 mL/min, significant liver disease, an existing heart valve or atrial fibrillation, or active bleeding were excluded from the AMPLIFY study. Patients were allowed to enter the study with or without prior parenteral anticoagulation (up to 48 hours).</p>     <p>A total of 5244 patients were evaluable for efficacy and were followed for a mean of 154 days in the ELIQUIS group and 152 days in the enoxaparin/warfarin group. The mean age was 57 years. The AMPLIFY study population was 59% male, 83% Caucasian, 8% Asian, and 4% Black. For patients randomized to warfarin, the mean percentage of time in therapeutic range (INR 2.0-3.0) was 60.9%.</p>     <p>Approximately 90% of patients enrolled in AMPLIFY had an unprovoked DVT or PE at baseline. The remaining 10% of patients with a provoked DVT or PE were required to have an additional ongoing risk factor in order to be randomized, which included previous episode of DVT or PE, immobilization, history of cancer, active cancer, and known prothrombotic genotype.</p>     <p>ELIQUIS was shown to be noninferior to enoxaparin/warfarin in the AMPLIFY study for the primary endpoint of recurrent symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related death over 6 months of therapy (Table 13).</p>     <div class="scrollingtable">     <table>       <caption>        <span>Table 13:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Efficacy Results in the AMPLIFY Study</span>       </caption>       <colgroup>       <col width="29%" />        <col width="23%" />        <col width="23%" />        <col width="40%" />       </colgroup>      <thead>        <tr class="First Last">         <th class="Botrule Toprule" valign="top"></th>        <th class="Botrule Toprule" valign="top">ELIQUIS <br />N=2609 <br />n</th>        <th class="Botrule Toprule" valign="top">Enoxaparin/Warfarin <br />N=2635 <br />n</th>        <th class="Botrule Toprule" valign="top">Relative Risk <br />(95% CI)</th>        </tr>       </thead>       <tfoot>        <tr class="First">         <td class="Botrule" align="left" colspan="4" valign="top">*&nbsp;&nbsp;&nbsp;Noninferior compared to enoxaparin/warfarin (P-value &lt;0.0001).</td>        </tr>        <tr class="Last">         <td class="Botrule" align="left" colspan="4" valign="top"><span class="Sup">†</span>&nbsp;&nbsp;&nbsp;Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.</td>        </tr>       </tfoot>       <tbody>        <tr class="First">         <td class="Toprule"> <p class="First">VTE or VTE-related death*</p> </td>        <td align="center"> <p class="First">59 (2.3%)</p> </td>        <td align="center"> <p class="First">71 (2.7%)</p> </td>        <td align="center"> <p class="First">0.84 (0.60, 1.18)</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;&nbsp;DVT<span class="Sup">†</span> </p> </td>        <td align="center"> <p class="First">22 (0.8%)</p> </td>        <td align="center"> <p class="First">35 (1.3%)</p> </td>        <td></td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;&nbsp;PE<span class="Sup">†</span> </p> </td>        <td align="center"> <p class="First">27 (1.0%)</p> </td>        <td align="center"> <p class="First">25 (0.9%)</p> </td>        <td></td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;&nbsp;VTE-related death<span class="Sup">†</span> </p> </td>        <td align="center"> <p class="First">12 (0.4%)</p> </td>        <td align="center"> <p class="First">16 (0.6%)</p> </td>        <td></td>        </tr>        <tr>         <td> <p class="First">VTE or all-cause death</p> </td>        <td align="center"> <p class="First">84 (3.2%)</p> </td>        <td align="center"> <p class="First">104 (4.0%)</p> </td>        <td align="center"> <p class="First">0.82 (0.61, 1.08)</p> </td>        </tr>        <tr class="Last">         <td class="Botrule"> <p class="First">VTE or CV-related death</p> </td>        <td class="Botrule" align="center"> <p class="First">61 (2.3%)</p> </td>        <td class="Botrule" align="center"> <p class="First">77 (2.9%)</p> </td>        <td class="Botrule" align="center"> <p class="First">0.80 (0.57, 1.11)</p> </td>        </tr>       </tbody>      </table>    </div>     <p>In the AMPLIFY study, patients were stratified according to their index event of PE (with or without DVT) or DVT (without PE). Efficacy in the initial treatment of VTE was consistent between the two subgroups.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_22156e98-e10c-4d8a-be6c-83b87f18920c"></a>    <a name="section-13.3.2"></a>     <p></p>     <h3>AMPLIFY-EXT</h3>     <p class="First">Patients who had been treated for DVT and/or PE for 6 to 12 months with anticoagulant therapy without having a recurrent event were randomized to treatment with ELIQUIS 2.5 mg orally twice daily, ELIQUIS 5 mg orally twice daily, or placebo for 12 months. Approximately one-third of patients participated in the AMPLIFY study prior to enrollment in the AMPLIFY-EXT study.</p>     <p>A total of 2482 patients were randomized to study treatment and were followed for a mean of approximately 330 days in the ELIQUIS group and 312 days in the placebo group. The mean age in the AMPLIFY-EXT study was 57 years. The study population was 57% male, 85% Caucasian, 5% Asian, and 3% Black.</p>     <p>The AMPLIFY-EXT study enrolled patients with either an unprovoked DVT or PE at baseline (approximately 92%) or patients with a provoked baseline event and one additional risk factor for recurrence (approximately 8%). However, patients who had experienced multiple episodes of unprovoked DVT or PE were excluded from the AMPLIFY-EXT study. In the AMPLIFY-EXT study, both doses of ELIQUIS were superior to placebo in the primary endpoint of symptomatic, recurrent VTE (nonfatal DVT or nonfatal PE), or all-cause death (Table 14).</p>     <div class="scrollingtable">     <table>       <caption>        <span>Table 14:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Efficacy Results in the AMPLIFY-EXT Study</span>       </caption>       <colgroup>       <col width="22%" />        <col width="17%" />        <col width="17%" />        <col width="17%" />        <col width="17%" />        <col width="24%" />       </colgroup>      <thead>        <tr class="First">         <th class="Rrule Toprule" valign="top"></th>        <th class="Lrule Toprule" valign="top"></th>        <th class="Toprule" valign="top"></th>        <th class="Rrule Toprule" valign="top"></th>        <th class="Lrule Toprule" colspan="2" valign="top">Relative Risk (95% CI)</th>        </tr>        <tr class="Last">         <th class="Botrule Rrule" valign="top"></th>        <th class="Botrule Lrule" valign="top">ELIQUIS <br />2.5 mg<br />N=840</th>        <th class="Botrule" valign="top">ELIQUIS <br />5 mg <br />N=813</th>        <th class="Botrule Rrule" valign="top">Placebo<br /> <br />N=829</th>        <th class="Botrule Lrule" valign="top">ELIQUIS <br />2.5 mg <br />vs Placebo</th>        <th class="Botrule" valign="top">ELIQUIS <br />5 mg <br />vs Placebo</th>        </tr>       </thead>       <tfoot>        <tr class="First Last">         <td class="Botrule" align="left" colspan="6" valign="top">*&nbsp;&nbsp;&nbsp;Patients with more than one event are counted in multiple rows.</td>        </tr>       </tfoot>       <tbody>        <tr class="First">         <td class="Botrule Rrule Toprule"></td>        <td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"> <p class="First">n (%)</p> </td>        <td class="Botrule Lrule Toprule"></td>        <td class="Botrule Toprule"></td>        </tr>        <tr>         <td class="Rrule Toprule"> <p class="First">Recurrent VTE or all-cause death</p> </td>        <td class="Lrule Toprule" align="center"> <p class="First">32 (3.8)</p> </td>        <td class="Toprule" align="center"> <p class="First">34 (4.2)</p> </td>        <td class="Rrule Toprule" align="center"> <p class="First">96 (11.6)</p> </td>        <td class="Lrule Toprule" align="center"> <p class="First">0.33 (0.22, 0.48)<br />p&lt;0.0001</p> </td>        <td class="Toprule" align="center"> <p class="First">0.36 (0.25, 0.53)<br />p&lt;0.0001</p> </td>        </tr>        <tr>         <td class="Rrule"> <p class="First">&nbsp;&nbsp;&nbsp;DVT*</p> </td>        <td class="Lrule" align="center"> <p class="First">19 (2.3)</p> </td>        <td align="center"> <p class="First">28 (3.4)</p> </td>        <td class="Rrule" align="center"> <p class="First">72 (8.7)</p> </td>        <td class="Lrule"></td>        <td></td>        </tr>        <tr>         <td class="Rrule"> <p class="First">&nbsp;&nbsp;&nbsp;PE*</p> </td>        <td class="Lrule" align="center"> <p class="First">23 (2.7)</p> </td>        <td align="center"> <p class="First">25 (3.1)</p> </td>        <td class="Rrule" align="center"> <p class="First">37 (4.5)</p> </td>        <td class="Lrule"></td>        <td></td>        </tr>        <tr class="Last">         <td class="Botrule Rrule"> <p class="First">&nbsp;&nbsp;&nbsp;All-cause death</p> </td>        <td class="Botrule Lrule" align="center"> <p class="First">22 (2.6)</p> </td>        <td class="Botrule" align="center"> <p class="First">25 (3.1)</p> </td>        <td class="Botrule Rrule" align="center"> <p class="First">33 (4.0)</p> </td>        <td class="Botrule Lrule"></td>        <td class="Botrule"></td>        </tr>       </tbody>      </table>    </div>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a> <div class="Section toggle-content closed" data-sectioncode="34069-5">   <a name="s16"></a>  <a name="section-14"></a>   <p></p>    <div class="Section" data-sectioncode="34069-5">    <a name="ID_9978b025-12c2-47f3-8cfc-ee6e9f49eb3c"></a>   <a name="section-14.1"></a>    <p></p>    <div class="Section" data-sectioncode="34069-5">     <a name="ID_b316b44c-8742-4191-8b4e-7041b6fd9150"></a>    <a name="section-14.1.1"></a>     <p></p>     <h3>How Supplied</h3>     <p class="First">ELIQUIS (apixaban) tablets are available as listed in the table below.</p>     <div class="scrollingtable">     <table>       <colgroup>       <col width="11%" />        <col width="21%" />        <col width="27%" />        <col width="28%" />        <col width="27%" />       </colgroup>      <thead>        <tr class="First Last">         <th class="Botrule Toprule" valign="top">Tablet <br />Strength</th>        <th class="Botrule Toprule" valign="top">Tablet<br />Color/Shape</th>        <th class="Botrule Toprule" valign="top">Tablet Markings</th>        <th class="Botrule Toprule" valign="top">Package Size</th>        <th class="Botrule Toprule" valign="top">NDC Code</th>        </tr>       </thead>       <tbody>        <tr class="First">         <td class="Botrule Toprule" align="center" rowspan="3"> <p class="First">2.5 mg</p> </td>        <td class="Botrule Toprule" rowspan="3"> <p class="First">Yellow, round, biconvex</p> </td>        <td class="Botrule Toprule" rowspan="3"> <p class="First">Debossed with “893” on one side and “2&frac12;” on the other side</p> </td>        <td class="Toprule" align="center"> <p class="First">Bottles of 60</p> </td>        <td class="Toprule" align="center"> <p class="First">0003-0893-21</p> </td>        </tr>        <tr>         <td align="center"> <p class="First">Bottles of 180</p> </td>        <td align="center"> <p class="First">0003-0893-41</p> </td>        </tr>        <tr>         <td class="Botrule" align="center"> <p class="First">Hospital Unit-Dose Blister <br />Package of 100</p> </td>        <td class="Botrule" align="center"> <p class="First">0003-0893-31</p> </td>        </tr>        <tr>         <td class="Botrule Toprule" align="center" rowspan="3"> <p class="First">5 mg</p> </td>        <td class="Botrule Toprule" rowspan="3"> <p class="First">Pink, oval, biconvex</p> </td>        <td class="Botrule Toprule" rowspan="3"> <p class="First">Debossed with “894” on one side and “5” on the other side</p> </td>        <td class="Toprule" align="center"> <p class="First">Bottles of 60</p> </td>        <td class="Toprule" align="center"> <p class="First">0003-0894-21</p> </td>        </tr>        <tr>         <td align="center"> <p class="First">Bottles of 180</p> </td>        <td align="center"> <p class="First">0003-0894-41</p> </td>        </tr>        <tr class="Last">         <td class="Botrule" align="center"> <p class="First">Hospital Unit-Dose Blister <br />Package of 100</p> </td>        <td class="Botrule" align="center"> <p class="First">0003-0894-31</p> </td>        </tr>       </tbody>      </table>    </div>    </div>   </div>   <div class="Section" data-sectioncode="44425-7">    <a name="ID_9e9c7c6f-f22d-440e-9d0f-964fb9e8c9a2"></a>   <a name="section-14.2"></a>    <p></p>    <div class="Section" data-sectioncode="44425-7">     <a name="ID_fe980c51-5e0e-436e-8443-c2f506f6e187"></a>    <a name="section-14.2.1"></a>     <p></p>     <h3>Storage and Handling</h3>     <p class="First">Store at 20&deg;C to 25&deg;C (68&deg;F-77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F-86&deg;F) [see USP Controlled Room Temperature].</p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">17 PATIENT COUNSELING INFORMATION</a> <div class="Section toggle-content closed" data-sectioncode="34076-0">   <a name="s17"></a>  <a name="section-15"></a>   <p></p>    <p class="First"> <span class="Italics">See FDA-approved patient labeling (Medication Guide).</span> </p>   <p>Advise patients of the following:</p>   <dl>    <dt>    ●   </dt>    <dd>    They should not discontinue ELIQUIS without talking to their physician first.   </dd>    <dt>    ●   </dt>    <dd>    They should be informed that it might take longer than usual for bleeding to stop, and they may bruise or bleed more easily when treated with ELIQUIS. Advise patients about how to recognize bleeding or symptoms of hypovolemia and of the urgent need to report any unusual bleeding to their physician.   </dd>    <dt>    ●   </dt>    <dd>    They should tell their physicians and dentists they are taking ELIQUIS, and/or any other product known to affect bleeding (including nonprescription products, such as aspirin or NSAIDs), before any surgery or medical or dental procedure is scheduled and before any new drug is taken.   </dd>    <dt>    ●   </dt>    <dd>    If the patient is having neuraxial anesthesia or spinal puncture, inform the patient to watch for signs and symptoms of spinal or epidural hematomas, such as numbness or weakness of the legs, or bowel or bladder dysfunction     <span class="Italics">[see <a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">Warnings and Precautions (5.3)</a>]</span>. If any of these symptoms occur, the patient should contact his or her physician immediately.   </dd>    <dt>    ●   </dt>    <dd>    They should tell their physicians if they are pregnant or plan to become pregnant or are breastfeeding or intend to breastfeed during treatment with ELIQUIS     <span class="Italics">[see <a href="#ID_47163af8-a468-4113-acd7-e6f01f361d71">Use in Specific Populations (8.1</a></span>,     <span class="Italics"><a href="#ID_49c34a2e-e9f2-40b3-94d0-9c14d350890b">8.3)</a>]</span>.   </dd>    <dt>    ●   </dt>    <dd>    If a dose is missed, the dose should be taken as soon as possible on the same day and twice-daily administration should be resumed. The dose should not be doubled to make up for a missed dose.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">SPL UNCLASSIFIED SECTION</a> <div class="Section toggle-content closed" data-sectioncode="42229-5">   <a name="sSign"></a>  <a name="section-16"></a>   <p></p>   <p class="First"> <br /> <br />Manufactured by:<br />Bristol-Myers Squibb Company<br />Princeton, New Jersey 08543 USA</p>   <p>Marketed by:<br />Bristol-Myers Squibb Company<br />Princeton, New Jersey 08543 USA<br />and<br />Pfizer Inc<br />New York, New York 10017 USA</p>   <p>Rotachrom<span class="Sup">&reg;</span> is a registered trademark of Diagnostica Stago.</p>   <p> <br />1289808A1 / 1289807A1 / 1298500A1 <br /> <br /> <br /> <br /> </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">MEDICATION GUIDE</a> <div class="Section toggle-content closed" data-sectioncode="42231-1">   <a name="ID_8eaa6df2-2d9a-4e43-94f6-b0dc66f2313b"></a>  <a name="section-17"></a>   <p></p>    <p class="First"> <span class="Bold">ELIQUIS<span class="Sup">&reg;</span></span> (ELL eh kwiss) <br /> <span class="Bold">(apixaban)</span> <br /> <span class="Bold">tablets</span> </p>   <p> <span class="Bold">What is the most important information I should know about ELIQUIS?</span> </p>   <dl>    <dt>    ●   </dt>    <dd>     <span class="Bold">For people taking ELIQUIS for atrial fibrillation:<br /> <br /> </span>People with atrial fibrillation (a type of irregular heartbeat) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. ELIQUIS lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking ELIQUIS, you may have increased risk of forming a clot in your blood.    <br />     <br />     <span class="Bold">Do not stop taking ELIQUIS without talking to the doctor who prescribes it for you. Stopping ELIQUIS increases your risk of having a stroke.</span>     <br />     <br />ELIQUIS may need to be stopped, if possible, prior to surgery or a medical or dental procedure. Ask the doctor who prescribed ELIQUIS for you when you should stop taking it. Your doctor will tell you when you may start taking ELIQUIS again after your surgery or procedure. If you have to stop taking ELIQUIS, your doctor may prescribe another medicine to help prevent a blood clot from forming.    <br />     <br />    </dd>    <dt>    ●   </dt>    <dd>     <span class="Bold">ELIQUIS can cause bleeding</span> which can be serious and rarely may lead to death. This is because ELIQUIS is a blood thinner medicine that reduces blood clotting.    <br />     <br />You may have a higher risk of bleeding if you take ELIQUIS and take other medicines that increase your risk of bleeding, including:    <br />     <dl>      <dt>      ●     </dt>      <dd>      aspirin or aspirin-containing products     </dd>      <dt>      ●     </dt>      <dd>      long-term (chronic) use of nonsteroidal anti-inflammatory drugs (NSAIDs)     </dd>      <dt>      ●     </dt>      <dd>      warfarin sodium (COUMADIN      <span class="Sup">&reg;</span>, JANTOVEN      <span class="Sup">&reg;</span>)     </dd>      <dt>      ●     </dt>      <dd>      any medicine that contains heparin     </dd>      <dt>      ●     </dt>      <dd>      selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)     </dd>      <dt>      ●     </dt>      <dd>      other medicines to help prevent or treat blood clots     </dd>     </dl>    </dd>    <dt>    &nbsp;   </dt>    <dd>     <br />Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above.    <br />     <br />While taking ELIQUIS:    <dl>      <dt>      ●     </dt>      <dd>      you may bruise more easily     </dd>      <dt>      ●     </dt>      <dd>      it may take longer than usual for any bleeding to stop     </dd>     </dl>    </dd>    <dt>    &nbsp;   </dt>    <dd>     <br />     <span class="Bold">Call your doctor or get medical help right away if you have any of these signs or symptoms of bleeding when taking ELIQUIS:</span>     <br />     <br />     <dl>      <dt>      ●     </dt>      <dd>      unexpected bleeding, or bleeding that lasts a long time, such as:       <dl>        <dt>        ●       </dt>        <dd>        unusual bleeding from the gums       </dd>        <dt>        ●       </dt>        <dd>        nosebleeds that happen often       </dd>        <dt>        ●       </dt>        <dd>        menstrual bleeding or vaginal bleeding that is heavier than normal       </dd>       </dl>      </dd>      <dt>      ●     </dt>      <dd>      bleeding that is severe or you cannot control     </dd>      <dt>      ●     </dt>      <dd>      red, pink, or brown urine     </dd>      <dt>      ●     </dt>      <dd>      red or black stools (looks like tar)     </dd>      <dt>      ●     </dt>      <dd>      cough up blood or blood clots     </dd>      <dt>      ●     </dt>      <dd>      vomit blood or your vomit looks like coffee grounds     </dd>      <dt>      ●     </dt>      <dd>      unexpected pain, swelling, or joint pain     </dd>      <dt>      ●     </dt>      <dd>      headaches, feeling dizzy or weak     </dd>     </dl>    </dd>    <dt>    ●   </dt>    <dd>     <span class="Bold">ELIQUIS is not for patients with artificial heart valves.</span>    </dd>    <dt>    ●   </dt>    <dd>     <span class="Bold">Spinal or epidural blood clots (hematoma).</span> People who take a blood thinner medicine (anticoagulant) like ELIQUIS, and have medicine injected into their spinal and epidural area, or have a spinal puncture have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if:    <dl>      <dt>      ●     </dt>      <dd>      a thin tube called an epidural catheter is placed in your back to give you certain medicine     </dd>      <dt>      ●     </dt>      <dd>      you take NSAIDs or a medicine to prevent blood from clotting     </dd>      <dt>      ●     </dt>      <dd>      you have a history of difficult or repeated epidural or spinal punctures     </dd>      <dt>      ●     </dt>      <dd>      you have a history of problems with your spine or have had surgery on your spine     </dd>     </dl>    </dd>    <dt>    &nbsp;   </dt>    <dd>     <br />If you take ELIQUIS and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots or bleeding. Tell your doctor right away if you have tingling, numbness, or muscle weakness, especially in your legs and feet.   </dd>   </dl>   <p> <span class="Bold">What is ELIQUIS?</span> </p>   <p>ELIQUIS is a prescription medicine used to:</p>   <dl>    <dt>    ●   </dt>    <dd>    reduce the risk of stroke and blood clots in people who have atrial fibrillation.   </dd>    <dt>    ●   </dt>    <dd>    reduce the risk of forming a blood clot in the legs and lungs of people who have just had hip or knee replacement surgery.   </dd>    <dt>    ●   </dt>    <dd>    treat blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism), and reduce the risk of them occurring again.   </dd>   </dl>   <p>It is not known if ELIQUIS is safe and effective in children.</p>   <p> <span class="Bold">Who should not take ELIQUIS?</span> </p>   <p> <span class="Bold">Do not take ELIQUIS if you:</span> </p>   <dl>    <dt>    ●   </dt>    <dd>    currently have certain types of abnormal bleeding.   </dd>    <dt>    ●   </dt>    <dd>    have had a serious allergic reaction to ELIQUIS. Ask your doctor if you are not sure.   </dd>   </dl>   <p> <span class="Bold">What should I tell my doctor before taking ELIQUIS?</span> </p>   <p> <span class="Bold">Before you take ELIQUIS, tell your doctor if you:</span> </p>   <dl>    <dt>    ●   </dt>    <dd>    have kidney or liver problems   </dd>    <dt>    ●   </dt>    <dd>    have any other medical condition   </dd>    <dt>    ●   </dt>    <dd>    have ever had bleeding problems   </dd>    <dt>    ●   </dt>    <dd>    are pregnant or plan to become pregnant. It is not known if ELIQUIS will harm your unborn baby.   </dd>    <dt>    ●   </dt>    <dd>    are breastfeeding or plan to breastfeed. It is not known if ELIQUIS passes into your breast milk. You and your doctor should decide if you will take ELIQUIS or breastfeed. You should not do both.   </dd>   </dl>   <p>Tell all of your doctors and dentists that you are taking ELIQUIS. They should talk to the doctor who prescribed ELIQUIS for you, before you have <span class="Bold">any</span> surgery, medical or dental procedure.</p>   <p> <span class="Bold">Tell your doctor about all the medicines you take, including</span> prescription and over-the-counter medicines, vitamins, and herbal supplements. Some of your other medicines may affect the way ELIQUIS works. Certain medicines may increase your risk of bleeding or stroke when taken with ELIQUIS. See &quot;<span class="Bold">What is the most important information I should know about ELIQUIS?</span>&quot;</p>   <p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>   <p> <span class="Bold">How should I take ELIQUIS?</span> </p>   <dl>    <dt>    ●   </dt>    <dd>     <span class="Bold">Take ELIQUIS exactly as prescribed by your doctor.</span>    </dd>    <dt>    ●   </dt>    <dd>    Take ELIQUIS twice every day with or without food.   </dd>    <dt>    ●   </dt>    <dd>    Do not change your dose or stop taking ELIQUIS unless your doctor tells you to.   </dd>    <dt>    ●   </dt>    <dd>    If you miss a dose of ELIQUIS, take it as soon as you remember. Do not take more than one dose of ELIQUIS at the same time to make up for a missed dose.   </dd>    <dt>    ●   </dt>    <dd>    Your doctor will decide how long you should take ELIQUIS.     <span class="Bold">Do not stop taking it without first talking with your doctor. If you are taking ELIQUIS for atrial fibrillation, stopping ELIQUIS may increase your risk of having a stroke.</span>    </dd>    <dt>    ●   </dt>    <dd>     <span class="Bold">Do not run out of ELIQUIS. Refill your prescription before you run out.</span> When leaving the hospital following hip or knee replacement, be sure that you will have ELIQUIS available to avoid missing any doses.   </dd>    <dt>    ●   </dt>    <dd>    If you take too much ELIQUIS, call your doctor or go to the nearest hospital emergency room right away.   </dd>    <dt>    ●   </dt>    <dd>    Call your doctor or healthcare provider right away if you fall or injure yourself, especially if you hit your head. Your doctor or healthcare provider may need to check you.   </dd>   </dl>   <p> <span class="Bold">What are the possible side effects of ELIQUIS?</span> </p>   <dl>    <dt>    ●   </dt>    <dd>    See &quot;    <span class="Bold">What is the most important information I should know about ELIQUIS?</span>&quot;   </dd>    <dt>    ●   </dt>    <dd>    ELIQUIS can cause a skin rash or severe allergic reaction. Call your doctor or get medical help right away if you have any of the following symptoms:    <dl>      <dt>      ●     </dt>      <dd>      chest pain or tightness     </dd>      <dt>      ●     </dt>      <dd>      swelling of your face or tongue     </dd>      <dt>      ●     </dt>      <dd>      trouble breathing or wheezing     </dd>      <dt>      ●     </dt>      <dd>      feeling dizzy or faint     </dd>     </dl>    </dd>   </dl>   <p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>   <p>These are not all of the possible side effects of ELIQUIS. For more information, ask your doctor or pharmacist.</p>   <p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>   <p> <span class="Bold">How should I store ELIQUIS?</span> </p>   <p>Store ELIQUIS at room temperature between 68&deg;F to 77&deg;F (20&deg;C to 25&deg;C).</p>   <p> <span class="Bold">Keep ELIQUIS and all medicines out of the reach of children.</span> </p>   <p> <span class="Bold">General Information about ELIQUIS</span> </p>   <p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ELIQUIS for a condition for which it was not prescribed. Do not give ELIQUIS to other people, even if they have the same symptoms that you have. It may harm them.</p>   <p>If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about ELIQUIS that is written for health professionals.</p>   <p>For more information, call 1-855-354-7847 (1-855-ELIQUIS) or go to www.ELIQUIS.com.</p>   <p> <span class="Bold">What are the ingredients in ELIQUIS?</span> </p>   <p>Active ingredient: apixaban.</p>   <p>Inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetin, and yellow iron oxide (2.5 mg tablets) or red iron oxide (5 mg tablets).</p>   <p>This Medication Guide has been approved by the U.S. Food and Drug Administration.<br /> <br /> <br /> <br />Manufactured by:<br />Bristol-Myers Squibb Company<br />Princeton, New Jersey 08543 USA</p>   <p>Marketed by:<br />Bristol-Myers Squibb Company<br />Princeton, New Jersey 08543 USA<br />and<br />Pfizer Inc<br />New York, New York 10017 USA</p>   <p> <br />COUMADIN<span class="Sup">&reg;</span> is a registered trademark of Bristol-Myers Squibb Pharma Company.</p>   <p>All other trademarks are property of their respective companies.</p>   <p> <br /> <br />1289808A1 / 1289807A1 / 1298500A1<br />1295958A1 <br /> <br />Revised August 2014<br /> <br /> </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">ELIQUIS 2.5 mg tablets Representative Packaging</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="ID_522f555d-082b-4f39-be83-efe263758431"></a>  <a name="section-18"></a>   <p></p>    <p class="First">See <span class="Bold">How Supplied</span> section for a complete list of available packages of ELIQUIS.</p>   <p>60 Tablets<br />NDC 0003-0893-21<br />ELIQUIS<span class="Sup">&reg;</span> <br />(apixaban) tablets<br />2.5 mg<br />DISPENSE WITH MEDICATION GUIDE<br />Rx only<br />Bristol-Myers Squibb<br />Pfizer</p>   <div class="Figure">    <a name="id15663880"></a>   <img src="image.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0&name=eliquis%2D2pt5mg%2D60slbl%2Ejpg" alt="Eliquis 2.5 mg 60s Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">ELIQUIS 5 mg tablets Representative Packaging</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="ID_0d93caff-207b-4aa1-829e-02439954331a"></a>  <a name="section-19"></a>   <p></p>    <p class="First">60 Tablets<br />NDC 0003-0894-21<br />ELIQUIS<span class="Sup">&reg;</span> <br />(apixaban) tablets<br />5 mg<br />DISPENSE WITH MEDICATION GUIDE<br />Rx only<br />Bristol-Myers Squibb<br />Pfizer</p>   <div class="Figure">    <a name="id15662442"></a>   <img src="image.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0&name=eliquis%2D5mg%2D60slbl%2Ejpg" alt="Eliquis 5 mg 60s Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INGREDIENTS AND APPEARANCE</a> <div class="DataElementsTables toggle-content">   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>ELIQUIS&nbsp; </strong> <br /> <span class="contentTableReg">apixaban tablet, film coated</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0003-0893</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>apixaban</strong> (UNII: 3Z9Y7UWC1J) (apixaban - UNII:3Z9Y7UWC1J)</td>          <td class="formItem">apixaban</td>          <td class="formItem">2.5&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>anhydrous lactose</strong> (UNII: 3SY5LH9PMK)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>cellulose, microcrystalline</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>croscarmellose sodium</strong> (UNII: M28OL1HH48)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium lauryl sulfate</strong> (UNII: 368GB5141J)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>magnesium stearate</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>lactose monohydrate</strong> (UNII: EWQ57Q8I5X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>triacetin</strong> (UNII: XHX3C3X673)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>ferric oxide yellow</strong> (UNII: EX438O2MRT)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">YELLOW</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">ROUND</td>          <td class="formLabel">Size</td>          <td class="formItem">6mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">893;2;1;2</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0003-0893-21</td>          <td class="formItem">60 in 1 BOTTLE, PLASTIC</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0003-0893-41</td>          <td class="formItem">180 in 1 BOTTLE, PLASTIC</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem">NDC:0003-0893-31</td>          <td class="formItem">10 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem"></td>          <td class="formItem">10 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202155</td>          <td class="formItem">12/28/2012</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>ELIQUIS&nbsp; </strong> <br /> <span class="contentTableReg">apixaban tablet, film coated</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0003-0894</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>apixaban</strong> (UNII: 3Z9Y7UWC1J) (apixaban - UNII:3Z9Y7UWC1J)</td>          <td class="formItem">apixaban</td>          <td class="formItem">5&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>anhydrous lactose</strong> (UNII: 3SY5LH9PMK)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>cellulose, microcrystalline</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>croscarmellose sodium</strong> (UNII: M28OL1HH48)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium lauryl sulfate</strong> (UNII: 368GB5141J)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>magnesium stearate</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>lactose monohydrate</strong> (UNII: EWQ57Q8I5X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>triacetin</strong> (UNII: XHX3C3X673)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>ferric oxide red</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">PINK</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">OVAL</td>          <td class="formLabel">Size</td>          <td class="formItem">10mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">894;5</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0003-0894-21</td>          <td class="formItem">60 in 1 BOTTLE, PLASTIC</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0003-0894-41</td>          <td class="formItem">180 in 1 BOTTLE, PLASTIC</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem">NDC:0003-0894-31</td>          <td class="formItem">10 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem"></td>          <td class="formItem">10 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">4</th>          <td class="formItem">NDC:0003-0894-91</td>          <td class="formItem">1 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">4</th>          <td class="formItem"></td>          <td class="formItem">14 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202155</td>          <td class="formItem">12/28/2012</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>E.R. Squibb &amp; Sons, L.L.C. (011550092) </td>      </tr>     </tbody>   </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li>                                            </ul>                                        <div class="control-nav">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                        </div>                                    </div>                        </article>                       <div class="articlefooternav">                       <h2>Find additional resources</h2> <strong>(also available in the <a href="#leftmenu">left menu</a>)</strong>                                              <h3>Safety</h3>                       <p>                                                            <a href="#boxedwarning" target="_blank">Boxed Warnings</a>,                                                                                                                     <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>,                                 <a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a>,                                 <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22apixaban%22+%29" target="_blank">Presence in Breast Milk</a>                                                   </p>                       <h3>Related Resources</h3>                       <p>                                                                                          <a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=apixaban" target="_blank">Medline Plus</a>,                                                       <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=apixaban" target="_blank">Clinical Trials</a>,                            <a href="#pubmed-menu" id="pubmed-bottom">PubMed</a>,                            <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=apixaban&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                                  </p>                       <h3>More Info on this Drug</h3>                       <p>                            <a href="#modal-label-archives" class="modal-open">View Label Archives</a>,                             <a href="#modal-rx-norm" class="modal-open">RxNorm</a>,                             <a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a>                        </p>                    </div>                </div>                                <div class="divider"></div>            </div>        </div>        <!-- Label Archives Modal --><div class="mfp-hide modal" id="modal-label-archives">        <div class="modal-wrapper">        <header><h2>View Label Archives for this drug</h2></header>        <div class="top">        							    	    																																			    																	    	    	                             		       	                                                                                                           <h3 class="long-title">ELIQUIS- apixaban tablet, film coated <br></h3>            <h4>Number of versions: 4</h4>        </div>        <div class="modal-content">                <table class="modal">                    <tbody><tr>                        <th>Published Date</th>                        <th>Version</th>                               <th>Files</th>                    </tr>                                        <tr>                        <td>Sep 4, 2014</td>                        <td>							                                4                             							(current)                         </td>                              <td>                        								                                                            <a class="view-link" href="dailymed/drugInfo.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0" title="View this Label">view</a><span class="sep"> | </span>                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=150258">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Apr 4, 2014</td>                        <td>							                                3                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=135921">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Feb 18, 2014</td>                        <td>							                                2                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=131525">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jan 15, 2013</td>                        <td>							                                1                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=97725">download</a>                                                    </td>                    </tr>                                    </tbody></table>        </div>        </div></div>        <!-- RxNorm Modal --><div class="mfp-hide modal" id="modal-rx-norm">        <div class="modal-wrapper">        <header><h2>RxNorm</h2></header>        <div class="top">            <h3 class="long-title">ELIQUIS- apixaban tablet, film coated <br></h3>        </div>        <div class="modal-content">        							    	    																																			    																	    	    	                             		       	                                                                                               			                            <table class="modal">                    <tbody><tr>                        <th></th>                        <th>RxCUI</th>                               <th>RxNorm NAME</th>                        <th>RxTTY</th>                    </tr>                                                                                                    <tr class="psn-rxtty">                                                                    <td>1</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1364435">1364435</a></td>                              <td>apixaban 2.5 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>2</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1364435">1364435</a></td>                              <td>apixaban 2.5 MG Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>3</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1364441">1364441</a></td>                              <td>Eliquis 2.5 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>4</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1364441">1364441</a></td>                              <td>apixaban 2.5 MG Oral Tablet [Eliquis]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>5</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1364441">1364441</a></td>                              <td>Eliquis 2.5 MG Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>6</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1364445">1364445</a></td>                              <td>apixaban 5 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>7</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1364445">1364445</a></td>                              <td>apixaban 5 MG Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>8</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1364447">1364447</a></td>                              <td>Eliquis 5 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>9</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1364447">1364447</a></td>                              <td>apixaban 5 MG Oral Tablet [Eliquis]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>10</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1364447">1364447</a></td>                              <td>Eliquis 5 MG Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                </tbody></table>                    </div>        </div></div><!-- Label RSS Modal --><div class="mfp-hide modal" id="modal-label-rss">        <header><h2>Get Label RSS Feed for this Drug</h2></header>        <div class="top">            <h3 class="long-title">ELIQUIS- apixaban tablet, film coated <br></h3>        </div>        <div class="modal-content">            <h4>To receive this label RSS feed</h4>            <p>Copy the URL below and paste it into your RSS Reader application.			<p><a href="https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0" target="_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0</a></p>            <h4>To receive all DailyMed Updates for the last seven days</h4>            <p>Copy the URL below and paste it into your RSS Reader application.</p>            <p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target="_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>            <h4>What will I get with the DailyMed RSS feed?</h4>            <p>DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.</p>            <p>DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.</p>            <h4>How to discontinue the RSS feed</h4>            <p>If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.</p>            <a href="dailymed/rss-updates.cfm" class="rss-icon"></a> <a href="dailymed/rss-updates.cfm">More about getting RSS News & Updates from DailyMed</a>        </div></div>    <!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div><div class="hide-on-mobile"></div>    <div class="mobilenav no-js">        <ul>            <li><a href="dailymed/index.cfm">Home</a></li>            <li>News                <ul>                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                    <li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>                </ul>            </li>            <li>Search                <ul>                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                    	                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>	                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                            <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                </ul>            </li>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                <li>NLM SPL Resources                    <ul>                        <li><a href="dailymed/spl-resources.cfm">Download Data</a>                            <ul>                                <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                            </ul>                        </li>                        <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                        <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                    </ul>                </li>                <li>Application Development Support                    <ul>                        <li><a href="dailymed/app-support.cfm">Resources</a>                            <ul>                                <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                            </ul>                        </li>                    </ul>                </li>                        <li><a href="dailymed/help.cfm">Help</a></li>                                </ul>    </div>    <footer class="mainFooter">        <div class="container">            <div class="three columns">             <div class="nihnlmlogoprint"><img src="/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>                <a href="/www.nlm.nih.gov/" class="logo" title="National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png" width="109" height="37" alt="National Library of Medicine | National Institutes of Health" title="National Library of Medicine | National Institutes of Health" /></a>            </div>                        <div id="share" class="thirteen columns">                <div class="footer-links">                    <ul class="primary">                        <li><a href="dailymed/about-dailymed.cfm" title="About DailyMed">About DailyMed</a><span>|</span></li>                        <li><a href="dailymed/contact-us.cfm" title="Contact Us">Contact Us</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/copyright.html" title="Copyright" target="_blank" rel="bookmark">Copyright</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/privacy.html" title="Privacy" target="_blank" rel="bookmark">Privacy</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/accessibility.html" title="Web Accessibility" target="_blank" rel="bookmark">Web Accessibility</a><span>|</span></li>                        <li><a href="/www.hon.ch/HONcode/Conduct.html?HONConduct393117" target="_blank" title="HONCode Certification">DailyMed is HONCode Certified</a></li>                    </ul>                    <ul class="secondary">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">National Institutes of Health</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">U.S. National Library of Medicine</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <ul class="secondary mobile">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">NIH</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">NLM</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <div class="social">                        Share                         <!-- AddThis Button BEGIN -->                        <noscript>: JavaScript needed for Sharing tools</noscript>                        <div class="addthis_toolbox addthis_default_style addthis_16x16_style">							                                                            	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AELIQUIS%2D%20Apixaban%20Tablet%2C%20Film%20Coated%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3De9481622%2D7cc6%2D418a%2Dacb6%2Dc5450daae9b0%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                            <a class="addthis_button_facebook"></a>                            <a class="addthis_button_twitter"></a>                            <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="width: 16px; height: 16px">                                <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span>                                <img style="width:17px; margin-top: -2px;" src="/dailymed/images/addthis-image.jpg" alt="Bookmark &amp; Share">                            </a>                        </div>                                                <!-- AddThis Button END -->                    </div>                                    </div>            </div>        </div>                <div class="divider"></div>    </footer>    <div class="divider"></div></div><div class="to-top"></div><!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div> <div class="hide-on-mobile"></div><!-- START OF SmartSource Data Collector TAG --><!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. --><!-- Version: 9.4.0 --><!-- Tag Builder Version: 3.3  --><!-- Created: 1/25/2012 11:57:33 PM --><script type="text/javascript" src="/dailymed/scripts/webtrends.min.js"></script><!-- ----------------------------------------------------------------------------------- --><!-- Warning: The two script blocks below must remain inline. Moving them to an external --><!-- JavaScript include file can cause serious problems with cross-domain tracking.      --><!-- ----------------------------------------------------------------------------------- --><script type="text/javascript">//<![CDATA[var _tag=new WebTrends();_tag.dcsGetId();//]]></script><script type="text/javascript">//<![CDATA[_tag.dcsCustom=function(){// Add custom parameters here.//_tag.DCSext.param_name=param_value;_tag.DCSext.dcsid=_tag.dcsid}_tag.trackAllEvents=true;_tag.dcsCollect();//]]></script><noscript><div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"/></div></noscript><!-- END OF SmartSource Data Collector TAG --><script type="text/javascript">    setTimeout(function(){var a=document.createElement("script");    var b=document.getElementsByTagName("script")[0];    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script><script type="text/javascript">    function getParameterByName(name) {        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),            results = regex.exec(location.search);        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));    }    /* Tracking label type on search pages */    function CE_READY() {        if(!getParameterByName('labeltype')){           CE2.set(1, "No Label Type");        }        else{            var labeltype = getParameterByName('labeltype');            if(labeltype == 'all'){                CE2.set(1, "All");            }            else if(labeltype == 'human'){                CE2.set(1, "Human");            }            else if(labeltype == 'animal'){                CE2.set(1, "Animal");            }            else{                CE2.set(1, "Unknown");            }        }    }</script>                    <!-- DAP Universal Analytics -->    <script language="javascript" id="_fed_an_ua_tag" src="/dailymed/scripts/Universal-Federated-Analytics-Min.2.0.js?agency=HHS&subagency=NIH&enhlink=true&dclink=true"></script>    <script src="/dailymed/scripts/preview-text.min.js"></script></body></html>    